<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147715</url>
  </required_header>
  <id_info>
    <org_study_id>1908T0911</org_study_id>
    <nct_id>NCT04147715</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Single-Ascending-Dose, and Food Effect Study to Assess the Safety, Tolerability, Ventricular Repolarization, and Pharmacokinetics of S-648414 in Healthy Adult Study Participants (Part 1); A Phase 1, Randomized, Double-Blind, Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of S-648414 and A Drug-Drug Interaction Study With the CYP3A Substrate, Midazolam, in Healthy Adult Study Participants (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of Part 1 of the study is to evaluate the safety and tolerability of&#xD;
      S-648414 after administration of a single oral dose of S-648414 in healthy adult study&#xD;
      participants.&#xD;
&#xD;
      The primary objective of Part 2 is to evaluate the safety and tolerability of S-648414 after&#xD;
      administration of multiple oral doses of S-648414 in healthy adult study participants.&#xD;
&#xD;
      The primary objectives of Part 3 are evaluate the safety and tolerability of S-648414 after&#xD;
      administration of multiple oral doses of S-648414 in healthy adult study participants, and to&#xD;
      evaluate the effect of S-648414 on the pharmacokinetics (PK) of dolutegravir and the effect&#xD;
      of dolutegravir on the PK of S-648414 in healthy adult study participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amendment 2 of the study Protocol added a third part (Part 3) to the study. The revised&#xD;
      Official Title for the Protocol is:&#xD;
&#xD;
      &quot;A Phase 1, Randomized, Double-Blind, Single-Ascending-Dose, and Food Effect Study to Assess&#xD;
      the Safety, Tolerability, Ventricular Repolarization, and Pharmacokinetics of S-648414 in&#xD;
      Healthy Adult Study Participants (Part 1); A Phase 1, Randomized, Double-Blind,&#xD;
      Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of&#xD;
      S-648414 and A Drug-Drug Interaction Study with the CYP3A Substrate, Midazolam, in Healthy&#xD;
      Adult Study Participants (Part 2); and A Phase 1 Open-Label Study to Assess the Effect of&#xD;
      S-648414 on the Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the&#xD;
      Pharmacokinetics of S-648414 in Healthy Adult Study Participants (Part 3)&quot;&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Actual">September 29, 2020</completion_date>
  <primary_completion_date type="Actual">September 22, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Parts 1 and 2 were blinded studies. Part 3 was an open-label study and, therefore, did not include blinding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From dosing on Day 1 or Day 14 up to 10 days post dose</time_frame>
    <description>A TEAE is any event not present before exposure to study drug or any event already present that worsens after exposure to study drug.&#xD;
A serious adverse event is any untoward medical occurrence that resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other event that may have jeopardized the participant or required intervention to prevent one of the outcomes above.&#xD;
The investigator assessed the intensity of each AE according to the following:&#xD;
Grade 1 (Mild): No or minimal interference with usual activities.&#xD;
Grade 2 (Moderate): More than minimal interference with usual activities, intervention indicated.&#xD;
Grade 3 (Severe): Inability to perform usual activities, intervention or hospitalization indicated.&#xD;
Grade 4 (Potentially life-threatening): Inability to perform self-care, intervention indicated to prevent permanent impairment, disability, or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Number of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>From the first dose up to 10 days after end of dosing (25 days); A TEAE was summarized to a given treatment if the event onset/worsening occurred any time after the dose of that treatment and before the dose of the next treatment.</time_frame>
    <description>A TEAE is any event not present before exposure to study drug or any event already present that worsens after exposure to study drug.&#xD;
A serious adverse event is any untoward medical occurrence that resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other event that may have jeopardized the participant or required intervention to prevent one of the outcomes above.&#xD;
The investigator assessed the intensity of each AE according to the following:&#xD;
Grade 1 (Mild): No or minimal interference with usual activities.&#xD;
Grade 2 (Moderate): More than minimal interference with usual activities, intervention indicated.&#xD;
Grade 3 (Severe): Inability to perform usual activities, intervention or hospitalization indicated.&#xD;
Grade 4 (Potentially life-threatening): Inability to perform self-care, intervention indicated to prevent permanent impairment, disability, or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Number of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>From the first dose up to Day 36; A TEAE was summarized to a given treatment if the event onset/worsening occurred any time after the dose of that treatment and before the dose of the next treatment.</time_frame>
    <description>A TEAE is any event not present before exposure to study drug or any event already present that worsens after exposure to study drug.&#xD;
A serious adverse event is any untoward medical occurrence that resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other event that may have jeopardized the participant or required intervention to prevent one of the outcomes above.&#xD;
The investigator assessed the intensity of each AE according to the following:&#xD;
Grade 1 (Mild): No or minimal interference with usual activities.&#xD;
Grade 2 (Moderate): More than minimal interference with usual activities, intervention indicated.&#xD;
Grade 3 (Severe): Inability to perform usual activities, intervention or hospitalization indicated.&#xD;
Grade 4 (Potentially life-threatening): Inability to perform self-care, intervention indicated to prevent permanent impairment, disability, or death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Maximum Plasma Concentration (Cmax) of S-648414</measure>
    <time_frame>Day 21 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose. Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Time to Maximum Plasma Concentration (Tmax) of S-648414</measure>
    <time_frame>Day 21 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose. Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Plasma Concentration of S-648414 at the End of the Dosing Interval τ (Cτ)</measure>
    <time_frame>Day 22 and Day 29 (24 hours post-dosing on Days 21 and 28)</time_frame>
    <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Area Under the Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) for S-648414</measure>
    <time_frame>Day 21 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose. Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).&#xD;
Area under the concentration-time curve over the dosing interval τ (24 hours) was calculated by the linear up/log down trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Apparent Total Clearance (CL/F) of S-648414</measure>
    <time_frame>Day 21 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose. Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).&#xD;
Apparent total clearance was calculated as CL/F = Dose/AUC0-τ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Maximum Plasma Concentration (Cmax) of Dolutegravir</measure>
    <time_frame>Day 7 and Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Time to Maximum Plasma Concentration (Tmax) of Dolutegravir</measure>
    <time_frame>Day 7 and Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Plasma Concentration of Dolutegravir at the End of the Dosing Interval τ (Cτ)</measure>
    <time_frame>Day 8 and Day 29 (24 hours post-dosing on Day 7 and Day 28).</time_frame>
    <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Area Under the Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) for Dolutegravir</measure>
    <time_frame>Day 7 and Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.&#xD;
Area under the concentration-time curve over the dosing interval τ (24 hours) was calculated by the linear up/log down trapezoidal method.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 3: Apparent Total Clearance (CL/F) of Dolutegravir</measure>
    <time_frame>Day 7 and Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.&#xD;
Apparent total clearance calculated as CL/F =Dose/AUC0-τ</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum Plasma Concentration (Cmax) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time to Maximum Plasma Concentration (Tmax) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration After Dosing (AUC0-last) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
    <description>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing, calculated by the linear trapezoidal method when concentrations are increasing and by the logarithmic trapezoidal method when concentrations are decreasing (linear up/log down trapezoidal method).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
    <description>Area under the concentration-time curve extrapolated from time zero to infinity defined as AUC0-last + (Clast/λz), where Clast is the last measurable plasma concentration and λz is the plasma terminal elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Terminal Elimination Half-life (t1/2,z) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
    <description>Terminal elimination half-life calculated as t1/2,z = (ln2)/λz, where λz is the terminal elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Terminal Elimination Rate Constant (λz) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Mean Residence Time (MRT) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
    <description>Mean residence time, calculated as MRT = AUMC0-inf / AUC0-inf, where AUMC0-inf is the area under the first moment curve extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent Total Clearance (CL/F) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
    <description>Apparent total clearance estimated according to: CL/F = Dose / AUC0-inf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Apparent Volume of Distribution in the Terminal Elimination Phase (Vz/F) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
    <description>Apparent volume of distribution in the terminal elimination phase was estimated according to: Vz /F = Dose / AUC0-inf / λz.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Fraction of S-648414 Dose Excreted in Urine From 0 to 96 Hours Postdose (Feu0-96)</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose (-12 to 0 hours), 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours postdose</time_frame>
    <description>The fraction of S-648414 dose excreted in urine from 0 to 96 hours postdose was calculated as:&#xD;
Cumulative amount of S-648414 excreted in urine from time zero to 96 hours postdose (Aeu0-96) / Dose × 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Renal Clearance (CLR) of S-648414</measure>
    <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose (-12 to 0 hours), 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours postdose</time_frame>
    <description>Renal clearance was estimated according to: CLR = cumulative amount of S-648414 excreted in urine from time zero to 96 hours postdose (Aeu0-96) / area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Maximum Plasma Concentration (Cmax) of S-648414 Following Single and Multiple-dose Administration</measure>
    <time_frame>Day 1 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose; Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time to Maximum Plasma Concentration (Tmax) of S-648414 Following Single and Multiple-dose Administration</measure>
    <time_frame>Day 1 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose; Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) of S-648414 Following Single and Multiple-dose Administration</measure>
    <time_frame>Day 1 and day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Area under the concentration-time curve over the dosing interval (24 hours) on Day 1 and Day 14, calculated by the linear up/log down trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Terminal Elimination Half-life (t1/2,z) of S-648414 Following Multiple-dose Administration</measure>
    <time_frame>Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
    <description>Terminal elimination half-life, where t1/2,z = (ln2)/λz on Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Terminal Elimination Rate Constant (λz) of S-648414 Following Multiple-dose Administration</measure>
    <time_frame>Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
    <description>Terminal elimination rate constant, where λz is the magnitude of the slope of the linear regression of the log concentration versus time profile during the terminal phase on Day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Total Clearance (CL/F) of S-648414 Following Multiple-dose Administration</measure>
    <time_frame>Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Apparent total clearance estimated according to: CL/F = Dose/AUC0-τ on Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Apparent Volume of Distribution in the Terminal Elimination Phase (Vz/F) of S-648414 Following Multiple-dose Administration</measure>
    <time_frame>Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
    <description>Apparent volume of distribution in the terminal elimination phase on Day 14, estimated according to: Vz /F = Dose/AUC0-τ/λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Fraction of S-648414 Dose Excreted in Urine Over the Dosing Interval (Feu0- τ) Following Multiple-dose Administration</measure>
    <time_frame>Day 14 0-24 hours postdose</time_frame>
    <description>Fraction of dose excreted in urine over the dosing interval τ (24 hours) on Day 14 calculated as Aeu0-τ/Dose × 100, where Aeu0-τ is the amount of drug excreted in urine over the dosing interval τ (24 hours).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Renal Clearance (CLR) of S-648414 Following Multiple-dose Administration</measure>
    <time_frame>Day 14 0-24 hours postdose</time_frame>
    <description>Renal clearance on Day 14, calculated as CLR = Aeu0-τ/AUC0-τ, where Aeu0-τ is the amount of drug excreted in urine over the dosing interval τ (24 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Maximum Plasma Concentration (Cmax) of Midazolam</measure>
    <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time to Maximum Plasma Concentration of Midazolam</measure>
    <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration After Dosing (AUC0-last) for Midazolam</measure>
    <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).&#xD;
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing, calculated by linear up/log down trapezoidal method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam</measure>
    <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).&#xD;
Area under the concentration-time curve extrapolated from time zero to infinity defined as AUC0-last + (Clast/λz), where Clast is the last measurable plasma concentration and λz is the plasma terminal elimination rate constant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Terminal Elimination Half-life for Midazolam</measure>
    <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Terminal Elimination Rate Constant for Midazolam</measure>
    <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Mean Residence Time for Midazolam</measure>
    <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).&#xD;
Mean residence time was calculated as MRT = AUMC0-inf/AUC0-inf where AUMC0-inf is the area under the first moment curve extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in Fridericia's Corrected QT Interval (QTcF)</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. The QT interval is a measure between Q and T wave in heart's electrical cycle. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
QT interval was corrected for heart rate using Fridericia's correction (QTcF). Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔQTcF) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QTcF as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1: Change From Baseline in Heart Rate (HR)</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median HR in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG values from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in HR (ΔHR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline HR as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in PR Interval</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. The PR interval is the time from the onset of the P-wave to the start of the next QRS complex. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median PR in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in PR interval (ΔPR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline PR as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Change From Baseline in QRS Interval</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. The QRS complex is a combination of the Q wave, R wave and S wave on an ECG tracing, and represents ventricular depolarization. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QRS in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in QRS interval (ΔQRS) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QRS as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
QT interval was corrected for heart rate using Fridericia's correction (QTcF). Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔQTcF) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QTcF as covariate.&#xD;
Placebo-corrected ΔQTcF (ΔΔQTcF) was calculated as the adjusted mean ΔQTcF in the S-648414 group minus adjusted mean ΔQTcF in the placebo group at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Placebo-corrected Change From Baseline in Heart Rate</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median HR in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured values from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔHR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline HR as covariate.&#xD;
Placebo-corrected ΔHR (ΔΔHR) was calculated as the adjusted mean ΔHR in the S-648414 group minus adjusted mean ΔHR in the placebo group at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Placebo-corrected Change From Baseline in PR Interval</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median PR interval in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔPR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline PR as covariate.&#xD;
Placebo-corrected ΔPR (ΔΔPR) was calculated as the adjusted mean ΔPR in the S-648414 group minus adjusted mean ΔPR in the placebo group at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Placebo-corrected Change From Baseline in QRS Duration</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QRS duration in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in QRS duration (ΔQRS) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QRS as covariate.&#xD;
Placebo-corrected ΔQRS (ΔΔQRS) was calculated as the adjusted mean ΔQRS in the S-648414 group minus adjusted mean ΔQRS in the placebo group at each time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Recorded Outlier Values for QTcF, HR, PR, and QRS</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>A participant was determined as an outlier if the following criteria (assessed separately) were met for the ECG intervals at any time point:&#xD;
QTcF:&#xD;
Treatment-emergent value of &gt; 450 and ≤ 480 ms when not present at Baseline (new onset)&#xD;
Treatment-emergent value of &gt; 480 and ≤ 500 ms when not present at Baseline (new onset)&#xD;
Treatment-emergent value of &gt; 500 ms when not present at Baseline (new onset)&#xD;
Increase of QTcF (ΔQTcF) from Baseline of &gt; 30 and ≤ 60 ms&#xD;
Increase of QTcF from Baseline &gt; 60 ms&#xD;
HR:&#xD;
Decrease of HR from Baseline &gt; 25% resulting in HR &lt; 50 bpm&#xD;
Increase of HR from Baseline &gt; 25% resulting in HR &gt; 100 bpm&#xD;
PR:&#xD;
Increase of PR from Baseline &gt; 25% resulting in PR &gt; 200 ms&#xD;
QRS:&#xD;
Increase of QRS from Baseline &gt; 25% resulting in QRS &gt; 120 ms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Number of Participants With Treatment-emergent Changes for T-wave Morphology and U-wave Presence</measure>
    <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>T-wave abnormalities were categorized as follows:&#xD;
Normal T wave: Any positive T wave not meeting any criterion below&#xD;
Flat T wave: T amplitude &lt; 1 mm (either positive or negative) including flat isoelectric line&#xD;
Notched T wave (+): Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of the positive T wave&#xD;
Biphasic: T wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T waves included)&#xD;
Normal T wave (-): T amplitude that is negative, without biphasic T wave or notches&#xD;
Notched T wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T wave&#xD;
U waves: Presence of abnormal U waves</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received a single oral dose of matching placebo in a fasted state on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 10 mg S-648414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 30 mg S-648414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 100 mg S-648414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 250 mg S-648414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 500 mg S-648414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: 1000 mg S-648414</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Placebo + Midazolam</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received matching placebo once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the placebo dose on Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: 50 mg S-648414 + Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: 30 mg S-648414 + Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: 100 mg S-648414 + Dolutegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 100 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: 200 mg S-648414 + Dolutegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 200 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-648414</intervention_name>
    <description>Tablet for oral administration</description>
    <arm_group_label>Part 1: 10 mg S-648414</arm_group_label>
    <arm_group_label>Part 1: 100 mg S-648414</arm_group_label>
    <arm_group_label>Part 1: 1000 mg S-648414</arm_group_label>
    <arm_group_label>Part 1: 250 mg S-648414</arm_group_label>
    <arm_group_label>Part 1: 30 mg S-648414</arm_group_label>
    <arm_group_label>Part 1: 500 mg S-648414</arm_group_label>
    <arm_group_label>Part 2: 30 mg S-648414 + Midazolam</arm_group_label>
    <arm_group_label>Part 2: 50 mg S-648414 + Midazolam</arm_group_label>
    <arm_group_label>Part 3: 100 mg S-648414 + Dolutegravir</arm_group_label>
    <arm_group_label>Part 3: 200 mg S-648414 + Dolutegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablet for oral administration</description>
    <arm_group_label>Part 1: Placebo</arm_group_label>
    <arm_group_label>Part 2: Placebo + Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Solution for oral administration</description>
    <arm_group_label>Part 2: 30 mg S-648414 + Midazolam</arm_group_label>
    <arm_group_label>Part 2: 50 mg S-648414 + Midazolam</arm_group_label>
    <arm_group_label>Part 2: Placebo + Midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir</intervention_name>
    <description>Tablet for oral administration</description>
    <arm_group_label>Part 3: 100 mg S-648414 + Dolutegravir</arm_group_label>
    <arm_group_label>Part 3: 200 mg S-648414 + Dolutegravir</arm_group_label>
    <other_name>TIVICAY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female adults ≥ 18 years in USA or ≥ 20 years in Japan to ≤ 55 years of age,&#xD;
             at the time of signing the informed consent form (ICF).&#xD;
&#xD;
             a) Specific to Japan sites: enrollment in Part 3 (Group I and J) will consist of only&#xD;
             White or Black or African American race.&#xD;
&#xD;
          2. Capable of giving signed informed consent&#xD;
&#xD;
          3. Body mass index (BMI) ≥ 18.5 to &lt; 32.0 kg/m² at the Screening visit．&#xD;
&#xD;
          4. Considered medically healthy as determined by the investigator or subinvestigator&#xD;
             (suitably qualified), based on medical history and clinical evaluations including&#xD;
             physical examination, clinical laboratory tests, vital sign measurements, and 12-lead&#xD;
             electrocardiogram (ECG) at Screening and at upon admission to the Clinical Research&#xD;
             Unit (CRU) and prior to administration of study intervention on Day 1.&#xD;
&#xD;
          5. Female study participants must not be a woman of childbearing potential and must&#xD;
             either be postmenopausal (defined as no menses for 12 months without an alternative&#xD;
             medical cause; follicle-stimulating hormone (FSH) to be tested for confirmation at&#xD;
             Screening) or premenopausal with 1 of the following documented: hysterectomy, tubal&#xD;
             ligation, bilateral salpingectomy, or bilateral oophorectomy.&#xD;
&#xD;
          6. Male study participants must agree to use contraception during the treatment period&#xD;
             and for at least 3 months after the last dose of study intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Considered by the investigator or subinvestigator (suitably qualified) to be&#xD;
             ineligible for the study due to a history of or current condition of significant&#xD;
             metabolic or endocrine, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal (GI), urological, immunological, neurological, or psychiatric&#xD;
             disorders with clinical manifestations.&#xD;
&#xD;
          2. History or presence of cancer in last 5 years except for non-melanoma skin cancers.&#xD;
&#xD;
          3. Risk factors for:&#xD;
&#xD;
               1. Torsades de Pointes (eg, heart failure, cardiomyopathy, or family history of Long&#xD;
                  QT Syndrome or Brugada Syndrome)&#xD;
&#xD;
               2. Unexplained syncope, sick sinus syndrome, second- or third-degree&#xD;
                  atrioventricular (AV) block, myocardial infarction, pulmonary congestion, cardiac&#xD;
                  arrhythmia, angina, prolonged QT interval, or conduction abnormalities&#xD;
&#xD;
          4. History of GI surgery or disease including, but not limited to, gastric band/gastric&#xD;
             resection and/or intestinal resection and/or duodenal disease (ie, celiac disease)&#xD;
             that may result in clinically significant malabsorption (except for an appendectomy).&#xD;
&#xD;
          5. History of hypersensitivity or severe side effects induced by a drug.&#xD;
&#xD;
          6. Any condition requiring medication and/or other treatment, such as dietary restriction&#xD;
             and physical therapy.&#xD;
&#xD;
          7. History of significant multiple and/or severe allergic symptoms including food allergy&#xD;
             (NOTE: Study participants with seasonal allergies may participate unless they have&#xD;
             ongoing symptoms).&#xD;
&#xD;
          8. Used drugs or substances known to be inducers or inhibitors of cytochrome P450 enzymes&#xD;
             and/or P-glycoprotein within 28 days prior to admission to the CRU.&#xD;
&#xD;
          9. Used prescription or over-the-counter (OTC) drugs, antacids, proton pump inhibitors,&#xD;
             H2 antagonists, Chinese herbal medicines, oral cannabidiol, vitamins, minerals,&#xD;
             herbal, and dietary supplements within 14 days prior to admission to the CRU.&#xD;
&#xD;
         10. Refuses to abstain from ingesting caffeine- or xanthine-containing&#xD;
             products/medications (eg, coffee, tea, cola drinks, other caffeinated beverages, or&#xD;
             chocolate) from 24 hours prior to admission to the CRU or refuses to refrain from&#xD;
             consuming such products throughout the study (including Follow-up period).&#xD;
&#xD;
         11. Consumed alcohol or used alcohol-containing products within 72 hours prior to&#xD;
             admission to the CRU or refuses to refrain from consuming such products throughout the&#xD;
             study (including Follow-up period).&#xD;
&#xD;
         12. History of recreational drug use in the previous 6 months, or has a history of&#xD;
             problematic alcohol use (defined as study participants who regularly consume excessive&#xD;
             amounts of alcohol, defined as &gt; 3 glasses of alcoholic beverages per day (1 glass is&#xD;
             approximately equivalent to: beer [284 mL/10 ounces (oz.)], wine [125 mL/4 oz.] or&#xD;
             distilled spirits [25 mL/1 oz.]).&#xD;
&#xD;
         13. A positive drug or alcohol screen at the Screening visit or upon admission to the CRU.&#xD;
&#xD;
         14. Used tobacco- or nicotine-containing products (including cigarette, pipe, cigar,&#xD;
             chewing, nicotine patch, nicotine gum, or Vaping product) within 6 months prior to&#xD;
             admission to the CRU or refuses to refrain from using tobacco- or nicotine-containing&#xD;
             products throughout the study (including Follow-up period).&#xD;
&#xD;
         15. Consumed grapefruit, grapefruit juice, Seville orange juice, orange juice, apple&#xD;
             juice, vegetables from the mustard green family (eg, kale, broccoli, watercress,&#xD;
             collard greens, kohlrabi, Brussels sprouts, mustard greens), or charbroiled meats&#xD;
             within 7 days prior to admission to the CRU or refuses to refrain from consuming such&#xD;
             products throughout the study (including Follow-up period).&#xD;
&#xD;
         16. A corrected QT (QTc) interval of &gt; 450 msec for males and &gt; 470 msec for females&#xD;
             (Fridericia's method) at the Screening visit or upon admission to the CRU.&#xD;
&#xD;
         17. Systolic blood pressure is outside the range of 90 to 140 mm Hg, diastolic blood&#xD;
             pressure is outside the range of 50 to 90 mm Hg, or pulse rate is outside the range of&#xD;
             40 to 100 beats per minute (bpm) or considered ineligible by the investigator or&#xD;
             subinvestigator at the Screening visit or upon admission to the CRU.&#xD;
&#xD;
         18. Total bilirubin, alanine aminotransferase (ALT), or aspartate aminotransferase (AST)&#xD;
             values are greater than the upper limit of normal (ULN), or estimated glomerular&#xD;
             filtration rate (eGFR) &lt; 90 mL/min/1.73 m² at Screening or upon admission to the CRU.&#xD;
&#xD;
         19. A positive serological test for untreated syphilis, positive hepatitis B surface&#xD;
             antigen, positive hepatitis C virus antibody, or positive human immunodeficiency virus&#xD;
             (HIV) antigen/antibody result at the Screening visit.&#xD;
&#xD;
         20. Participated in any other investigational trials or has been exposed to other&#xD;
             investigational drugs within 28 days or 5 half-lives of the previously administered&#xD;
             investigational drug (date derived from last study procedure [blood collection or&#xD;
             dosing] of previous trial), whichever is longer, prior to admission to the CRU.&#xD;
&#xD;
         21. Previously received S-648414.&#xD;
&#xD;
         22. Poor venous access.&#xD;
&#xD;
         23. Donated blood or had significant blood loss within 56 days of study admission to the&#xD;
             CRU or donated plasma within 7 days prior to until admission to the CRU.&#xD;
&#xD;
         24. Considered inappropriate for participation in the study for any reason by the&#xD;
             investigator or subinvestigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PPD Ph 1 Clinical Research Unit</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P-One Clinic</name>
      <address>
        <city>Hachioji City</city>
        <state>Toyko</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <results_first_submitted>September 20, 2021</results_first_submitted>
  <results_first_submitted_qc>September 20, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 20, 2021</results_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>S-648414</keyword>
  <keyword>Food effect</keyword>
  <keyword>Antiretroviral</keyword>
  <keyword>Drug-drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT04147715/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 10, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT04147715/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study consisted of Part 1 (single ascending dose [SAD], food effect, and effects on electrocardiogram [ECG] parameters), Part 2 (multiple ascending dose [MAD] and drug-drug interaction with midazolam, a CYP3A substrate), and Part 3 (the effect of S-648414 on the pharmacokinetics (PK) of dolutegravir and the effect of dolutegravir on the PK of S-648414).&#xD;
Parts 1 and 2 were conducted at a single site in the United States, and Part 3 was conducted at a single site in Japan.</recruitment_details>
      <pre_assignment_details>In Part 1 healthy participants were sequentially assigned to 1 of 6 ascending dose groups; within each dose group participants were randomized in a 3:1 ratio (4:1 in the 100 mg dose group) to receive S-648414 or placebo.&#xD;
In Part 2 healthy participants were assigned to 1 of 2 dose groups with 8 study participants randomized to receive S-648414 and 2 study participants receiving placebo per group.&#xD;
In Part 3 healthy participants were enrolled in 1 of 2 dose groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Placebo</title>
          <description>Participants received a single oral dose of matching placebo to S-648414 in a fasted state on Day 1. Two participants assigned to the 100 mg dose cohort also received a single oral dose of matching placebo in a fed state (after a high-fat meal) on Day 14.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: 10 mg S-648414</title>
          <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: 30 mg S-648414</title>
          <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1: 100 mg S-648414</title>
          <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
        </group>
        <group group_id="P5">
          <title>Part 1: 250 mg S-648414</title>
          <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 1: 500 mg S-648414</title>
          <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Part 1: 1000 mg S-648414</title>
          <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>Part 2: Placebo + Midazolam</title>
          <description>Participants received matching placebo to S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the placebo dose on Day 14.</description>
        </group>
        <group group_id="P9">
          <title>Part 2: 50 mg S-648414 + Midazolam</title>
          <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
        </group>
        <group group_id="P10">
          <title>Part 2: 30 mg S-648414 + Midazolam</title>
          <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
        </group>
        <group group_id="P11">
          <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
          <description>Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 100 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
        </group>
        <group group_id="P12">
          <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
          <description>Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 200 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="8"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="14"/>
                <participants group_id="P12" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="7"/>
                <participants group_id="P10" count="8"/>
                <participants group_id="P11" count="14"/>
                <participants group_id="P12" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Placebo</title>
          <description>Participants received a single oral dose of matching placebo to S-648414 in a fasted state on Day 1. Two participants assigned to the 100 mg dose cohort also received a single oral dose of matching placebo in a fed state (after a high-fat meal) on Day 14.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: 10 mg S-648414</title>
          <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1: 30 mg S-648414</title>
          <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1: 100 mg S-648414</title>
          <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1 followed by a single dose of S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
        </group>
        <group group_id="B5">
          <title>Part 1: 250 mg S-648414</title>
          <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 1: 500 mg S-648414</title>
          <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Part 1: 1000 mg S-648414</title>
          <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Part 2: Placebo + Midazolam</title>
          <description>Participants received matching placebo to S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the placebo dose on Day 14.</description>
        </group>
        <group group_id="B9">
          <title>Part 2: 50 mg S-648414 + Midazolam</title>
          <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
        </group>
        <group group_id="B10">
          <title>Part 2: 30 mg S-648414 + Midazolam</title>
          <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
        </group>
        <group group_id="B11">
          <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
          <description>Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 100 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
        </group>
        <group group_id="B12">
          <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
          <description>Participants received 50 mg dolutegravir orally once a day on Days 1 to 7, 200 mg S-648414 orally once a day on Days 15 to 21, and 50 mg dolutegravir co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="8"/>
            <count group_id="B10" value="8"/>
            <count group_id="B11" value="14"/>
            <count group_id="B12" value="14"/>
            <count group_id="B13" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Age data are reported separately for each part of the study.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Part 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="8.53"/>
                    <measurement group_id="B2" value="38.0" spread="10.55"/>
                    <measurement group_id="B3" value="40.3" spread="8.98"/>
                    <measurement group_id="B4" value="35.5" spread="7.80"/>
                    <measurement group_id="B5" value="28.5" spread="5.68"/>
                    <measurement group_id="B6" value="32.5" spread="14.87"/>
                    <measurement group_id="B7" value="36.5" spread="11.22"/>
                    <measurement group_id="B13" value="34.8" spread="9.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="4"/>
                    <count group_id="B9" value="8"/>
                    <count group_id="B10" value="8"/>
                    <count group_id="B11" value="0"/>
                    <count group_id="B12" value="0"/>
                    <count group_id="B13" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B8" value="36.0" spread="10.03"/>
                    <measurement group_id="B9" value="37.3" spread="9.97"/>
                    <measurement group_id="B10" value="34.4" spread="7.03"/>
                    <measurement group_id="B13" value="35.9" spread="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Part 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="0"/>
                    <count group_id="B8" value="0"/>
                    <count group_id="B9" value="0"/>
                    <count group_id="B10" value="0"/>
                    <count group_id="B11" value="14"/>
                    <count group_id="B12" value="14"/>
                    <count group_id="B13" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B11" value="35.4" spread="6.70"/>
                    <measurement group_id="B12" value="34.9" spread="6.32"/>
                    <measurement group_id="B13" value="35.1" spread="6.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="4"/>
                    <count group_id="B9" value="8"/>
                    <count group_id="B10" value="8"/>
                    <count group_id="B11" value="14"/>
                    <count group_id="B12" value="14"/>
                    <count group_id="B13" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="14"/>
                    <measurement group_id="B13" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="4"/>
                    <count group_id="B9" value="8"/>
                    <count group_id="B10" value="8"/>
                    <count group_id="B11" value="14"/>
                    <count group_id="B12" value="14"/>
                    <count group_id="B13" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="14"/>
                    <measurement group_id="B13" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="6"/>
                    <count group_id="B4" value="8"/>
                    <count group_id="B5" value="6"/>
                    <count group_id="B6" value="6"/>
                    <count group_id="B7" value="6"/>
                    <count group_id="B8" value="4"/>
                    <count group_id="B9" value="8"/>
                    <count group_id="B10" value="8"/>
                    <count group_id="B11" value="14"/>
                    <count group_id="B12" value="14"/>
                    <count group_id="B13" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="12"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>A TEAE is any event not present before exposure to study drug or any event already present that worsens after exposure to study drug.&#xD;
A serious adverse event is any untoward medical occurrence that resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other event that may have jeopardized the participant or required intervention to prevent one of the outcomes above.&#xD;
The investigator assessed the intensity of each AE according to the following:&#xD;
Grade 1 (Mild): No or minimal interference with usual activities.&#xD;
Grade 2 (Moderate): More than minimal interference with usual activities, intervention indicated.&#xD;
Grade 3 (Severe): Inability to perform usual activities, intervention or hospitalization indicated.&#xD;
Grade 4 (Potentially life-threatening): Inability to perform self-care, intervention indicated to prevent permanent impairment, disability, or death.</description>
        <time_frame>From dosing on Day 1 or Day 14 up to 10 days post dose</time_frame>
        <population>The safety analysis population included all participants randomly assigned to study intervention who took at least 1 dose of study intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo - Fasted</title>
            <description>Participants received a single oral dose of matching placebo to S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: Placebo - Fed</title>
            <description>Participants received a single dose of matching placebo to S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O9">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>A TEAE is any event not present before exposure to study drug or any event already present that worsens after exposure to study drug.&#xD;
A serious adverse event is any untoward medical occurrence that resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other event that may have jeopardized the participant or required intervention to prevent one of the outcomes above.&#xD;
The investigator assessed the intensity of each AE according to the following:&#xD;
Grade 1 (Mild): No or minimal interference with usual activities.&#xD;
Grade 2 (Moderate): More than minimal interference with usual activities, intervention indicated.&#xD;
Grade 3 (Severe): Inability to perform usual activities, intervention or hospitalization indicated.&#xD;
Grade 4 (Potentially life-threatening): Inability to perform self-care, intervention indicated to prevent permanent impairment, disability, or death.</description>
          <population>The safety analysis population included all participants randomly assigned to study intervention who took at least 1 dose of study intervention.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE with severity Grade 2 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE with severity Grade 3 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any ocular AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse events (SAEs)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to study discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to study drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 2: Number of Participants With Treatment-emergent Adverse Events</title>
        <description>A TEAE is any event not present before exposure to study drug or any event already present that worsens after exposure to study drug.&#xD;
A serious adverse event is any untoward medical occurrence that resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other event that may have jeopardized the participant or required intervention to prevent one of the outcomes above.&#xD;
The investigator assessed the intensity of each AE according to the following:&#xD;
Grade 1 (Mild): No or minimal interference with usual activities.&#xD;
Grade 2 (Moderate): More than minimal interference with usual activities, intervention indicated.&#xD;
Grade 3 (Severe): Inability to perform usual activities, intervention or hospitalization indicated.&#xD;
Grade 4 (Potentially life-threatening): Inability to perform self-care, intervention indicated to prevent permanent impairment, disability, or death.</description>
        <time_frame>From the first dose up to 10 days after end of dosing (25 days); A TEAE was summarized to a given treatment if the event onset/worsening occurred any time after the dose of that treatment and before the dose of the next treatment.</time_frame>
        <population>The safety analysis population included all participants randomly assigned to study intervention who took at least 1 dose of study intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Midazolam (Day -2)</title>
            <description>Participants received a single oral dose of 5 mg midazolam on Day -2.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: Placebo (Days 1-13)</title>
            <description>Participants received matching placebo to S-648414 orally once a day on Days 1 to 13.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: 50 mg S-648414 (Days 1-13)</title>
            <description>Participants received 50 mg S-648414 orally once a day on Days 1 to 13.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 30 mg S-648414 (Days 1-13)</title>
            <description>Participants received 30 mg S-648414 orally once a day on Days 1 to 13.</description>
          </group>
          <group group_id="O5">
            <title>Part 2: Placebo + Midazolam (Day 14)</title>
            <description>Participants received matching placebo to S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
          <group group_id="O6">
            <title>Part 2: 50 mg S-648414 + Midazolam (Day 14)</title>
            <description>Participants received 50 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: 30 mg S-648414 + Midazolam (Day 14)</title>
            <description>Participants received 30 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Number of Participants With Treatment-emergent Adverse Events</title>
          <description>A TEAE is any event not present before exposure to study drug or any event already present that worsens after exposure to study drug.&#xD;
A serious adverse event is any untoward medical occurrence that resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other event that may have jeopardized the participant or required intervention to prevent one of the outcomes above.&#xD;
The investigator assessed the intensity of each AE according to the following:&#xD;
Grade 1 (Mild): No or minimal interference with usual activities.&#xD;
Grade 2 (Moderate): More than minimal interference with usual activities, intervention indicated.&#xD;
Grade 3 (Severe): Inability to perform usual activities, intervention or hospitalization indicated.&#xD;
Grade 4 (Potentially life-threatening): Inability to perform self-care, intervention indicated to prevent permanent impairment, disability, or death.</description>
          <population>The safety analysis population included all participants randomly assigned to study intervention who took at least 1 dose of study intervention.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="7"/>
                <count group_id="O7" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE with severity Grade 2 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE with severity Grade 3 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any ocular AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to study discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to study drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Number of Participants With Treatment-emergent Adverse Events</title>
        <description>A TEAE is any event not present before exposure to study drug or any event already present that worsens after exposure to study drug.&#xD;
A serious adverse event is any untoward medical occurrence that resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other event that may have jeopardized the participant or required intervention to prevent one of the outcomes above.&#xD;
The investigator assessed the intensity of each AE according to the following:&#xD;
Grade 1 (Mild): No or minimal interference with usual activities.&#xD;
Grade 2 (Moderate): More than minimal interference with usual activities, intervention indicated.&#xD;
Grade 3 (Severe): Inability to perform usual activities, intervention or hospitalization indicated.&#xD;
Grade 4 (Potentially life-threatening): Inability to perform self-care, intervention indicated to prevent permanent impairment, disability, or death.</description>
        <time_frame>From the first dose up to Day 36; A TEAE was summarized to a given treatment if the event onset/worsening occurred any time after the dose of that treatment and before the dose of the next treatment.</time_frame>
        <population>The safety analysis population included all participants randomly assigned to study intervention who took at least 1 dose of study intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: Dolutegravir (100 mg S-648414 Group)</title>
            <description>Participants assigned to the 100 mg S-648414 dose group received 50 mg dolutegravir orally once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414</title>
            <description>Participants received 100 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: Dolutegravir (200 mg S-648414 Group)</title>
            <description>Participants assigned to the 200 mg S-648414 dose group received 50 mg dolutegravir once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O5">
            <title>Part 3: 200 mg S-648414</title>
            <description>Participants received 200 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O6">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Number of Participants With Treatment-emergent Adverse Events</title>
          <description>A TEAE is any event not present before exposure to study drug or any event already present that worsens after exposure to study drug.&#xD;
A serious adverse event is any untoward medical occurrence that resulted in death, was life-threatening, required or prolonged inpatient hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other event that may have jeopardized the participant or required intervention to prevent one of the outcomes above.&#xD;
The investigator assessed the intensity of each AE according to the following:&#xD;
Grade 1 (Mild): No or minimal interference with usual activities.&#xD;
Grade 2 (Moderate): More than minimal interference with usual activities, intervention indicated.&#xD;
Grade 3 (Severe): Inability to perform usual activities, intervention or hospitalization indicated.&#xD;
Grade 4 (Potentially life-threatening): Inability to perform self-care, intervention indicated to prevent permanent impairment, disability, or death.</description>
          <population>The safety analysis population included all participants randomly assigned to study intervention who took at least 1 dose of study intervention.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE with severity Grade 2 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE with severity Grade 3 to 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any ocular AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any treatment-related SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to study discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE leading to study drug discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Maximum Plasma Concentration (Cmax) of S-648414</title>
        <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).</description>
        <time_frame>Day 21 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose. Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population includes all study participants with at least 1 PK parameter estimated appropriately.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: 100 mg S-648414</title>
            <description>Participants received 100 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: 200 mg S-648414</title>
            <description>Participants received 200 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Maximum Plasma Concentration (Cmax) of S-648414</title>
          <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).</description>
          <population>The PK parameter population includes all study participants with at least 1 PK parameter estimated appropriately.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2740" spread="20.3"/>
                    <measurement group_id="O2" value="2720" spread="21.3"/>
                    <measurement group_id="O3" value="5150" spread="14.1"/>
                    <measurement group_id="O4" value="5020" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effect of dolutegravir on the PK of S-648414 was assessed by analysis of variance (ANOVA) fit with a linear mixed effect model with the natural log (ln)-transformed Cmax as the dependent variable, treatment as fixed effect, and participant as random effect. The difference and 90% confidence interval (CI) between the ln-transformed Cmax of S-648414 + dolutegravir and S-648414 alone were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of S-648414 were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.9913</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9232</ci_lower_limit>
            <ci_upper_limit>1.0645</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / S-648414</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of dolutegravir on the PK of S-648414 was assessed by an ANOVA fitted with a linear mixed effect model with the natural log-transformed Cmax as the dependent variable, treatment as fixed effect, and participant as random effect. The difference and 90% CI between the ln-transformed Cmax of S-648414 + dolutegravir and S-648414 alone were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of S-648414 were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.9754</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8916</ci_lower_limit>
            <ci_upper_limit>1.0671</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / S-648414</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Time to Maximum Plasma Concentration (Tmax) of S-648414</title>
        <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).</description>
        <time_frame>Day 21 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose. Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: 100 mg S-648414</title>
            <description>Participants received 100 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: 200 mg S-648414</title>
            <description>Participants received 200 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Time to Maximum Plasma Concentration (Tmax) of S-648414</title>
          <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).</description>
          <population>The PK parameter population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.25" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O3" value="2.50" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.25" lower_limit="1.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Plasma Concentration of S-648414 at the End of the Dosing Interval τ (Cτ)</title>
        <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).</description>
        <time_frame>Day 22 and Day 29 (24 hours post-dosing on Days 21 and 28)</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: 100 mg S-648414</title>
            <description>Participants received 100 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: 200 mg S-648414</title>
            <description>Participants received 200 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Plasma Concentration of S-648414 at the End of the Dosing Interval τ (Cτ)</title>
          <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).</description>
          <population>The PK parameter population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1210" spread="27.7"/>
                    <measurement group_id="O2" value="1250" spread="16.3"/>
                    <measurement group_id="O3" value="2590" spread="16.5"/>
                    <measurement group_id="O4" value="2360" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effect of dolutegravir on the PK of S-648414 was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed Cτ as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed Cτ of S-648414 + dolutegravir and S-648414 alone were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of S-648414 were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.0353</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9421</ci_lower_limit>
            <ci_upper_limit>1.1377</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / S-648414</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of dolutegravir on the PK of S-648414 was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed Cτ as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed Cτ of S-648414 + dolutegravir and S-648414 alone were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of S-648414 were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.9096</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8791</ci_lower_limit>
            <ci_upper_limit>0.9411</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / S-648414</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Area Under the Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) for S-648414</title>
        <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).&#xD;
Area under the concentration-time curve over the dosing interval τ (24 hours) was calculated by the linear up/log down trapezoidal method.</description>
        <time_frame>Day 21 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose. Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: 100 mg S-648414</title>
            <description>Participants received 100 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: 200 mg S-648414</title>
            <description>Participants received 200 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Area Under the Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) for S-648414</title>
          <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).&#xD;
Area under the concentration-time curve over the dosing interval τ (24 hours) was calculated by the linear up/log down trapezoidal method.</description>
          <population>The PK parameter population</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40800" spread="17.6"/>
                    <measurement group_id="O2" value="41080" spread="15.4"/>
                    <measurement group_id="O3" value="81010" spread="11.4"/>
                    <measurement group_id="O4" value="79820" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effect of dolutegravir on the PK of S-648414 was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed AUC0-τ as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed AUC0-τ of S-648414 + dolutegravir and S-648414 alone were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of S-648414 were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.0071</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9679</ci_lower_limit>
            <ci_upper_limit>1.0479</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / S-648414</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of dolutegravir on the PK of S-648414 was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed AUC0-τ as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed AUC0-τ of S-648414 + dolutegravir and S-648414 alone were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of S-648414 were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.9852</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9605</ci_lower_limit>
            <ci_upper_limit>1.0105</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / S-648414</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Apparent Total Clearance (CL/F) of S-648414</title>
        <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).&#xD;
Apparent total clearance was calculated as CL/F = Dose/AUC0-τ</description>
        <time_frame>Day 21 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8 and 12 hours postdose. Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: 100 mg S-648414</title>
            <description>Participants received 100 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: 200 mg S-648414</title>
            <description>Participants received 200 mg S-648414 orally once a day on Days 15 to 21.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Apparent Total Clearance (CL/F) of S-648414</title>
          <description>The effect of dolutegravir on the pharmacokinetics (PK) of S-648414 was assessed after administration of multiple oral doses of S-648414 alone (Day 21) and after administration of multiple oral doses of S-648414 co-administered with dolutegravir (Day 28).&#xD;
Apparent total clearance was calculated as CL/F = Dose/AUC0-τ</description>
          <population>The PK parameter population</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" spread="17.6"/>
                    <measurement group_id="O2" value="2.43" spread="15.4"/>
                    <measurement group_id="O3" value="2.47" spread="11.4"/>
                    <measurement group_id="O4" value="2.51" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Maximum Plasma Concentration (Cmax) of Dolutegravir</title>
        <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.</description>
        <time_frame>Day 7 and Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: Dolutegravir (100 mg S-648414 Group)</title>
            <description>Participants assigned to the 100 mg S-648414 dose group received 50 mg dolutegravir orally once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: Dolutegravir (200 mg S-648414 Group)</title>
            <description>Participants assigned to the 200 mg S-648414 dose group received 50 mg dolutegravir once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Maximum Plasma Concentration (Cmax) of Dolutegravir</title>
          <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.</description>
          <population>The PK parameter population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4910" spread="15.9"/>
                    <measurement group_id="O2" value="5800" spread="12.2"/>
                    <measurement group_id="O3" value="4720" spread="19.6"/>
                    <measurement group_id="O4" value="4950" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the plasma PK of dolutegravir was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed Cmax as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed Cmax of dolutegravir plus S-648414 and dolutegravir alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of dolutegravir were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.1806</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1171</ci_lower_limit>
            <ci_upper_limit>1.2477</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / Dolutegravir</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the plasma PK of dolutegravir was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed Cmax as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed Cmax of dolutegravir plus S-648414 and dolutegravir alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of dolutegravir were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.0480</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9656</ci_lower_limit>
            <ci_upper_limit>1.1373</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / Dolutegravir</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Time to Maximum Plasma Concentration (Tmax) of Dolutegravir</title>
        <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.</description>
        <time_frame>Day 7 and Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: Dolutegravir (100 mg S-648414 Group)</title>
            <description>Participants assigned to the 100 mg S-648414 dose group received 50 mg dolutegravir orally once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: Dolutegravir (200 mg S-648414 Group)</title>
            <description>Participants assigned to the 200 mg S-648414 dose group received 50 mg dolutegravir once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Time to Maximum Plasma Concentration (Tmax) of Dolutegravir</title>
          <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.</description>
          <population>The PK parameter population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.75" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O3" value="3.50" lower_limit="1.00" upper_limit="5.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="1.50" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Plasma Concentration of Dolutegravir at the End of the Dosing Interval τ (Cτ)</title>
        <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.</description>
        <time_frame>Day 8 and Day 29 (24 hours post-dosing on Day 7 and Day 28).</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: Dolutegravir (100 mg S-648414 Group)</title>
            <description>Participants assigned to the 100 mg S-648414 dose group received 50 mg dolutegravir orally once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: Dolutegravir (200 mg S-648414 Group)</title>
            <description>Participants assigned to the 200 mg S-648414 dose group received 50 mg dolutegravir once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Plasma Concentration of Dolutegravir at the End of the Dosing Interval τ (Cτ)</title>
          <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.</description>
          <population>The PK parameter population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1980" spread="23.1"/>
                    <measurement group_id="O2" value="2660" spread="17.6"/>
                    <measurement group_id="O3" value="1850" spread="25.7"/>
                    <measurement group_id="O4" value="2000" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the plasma PK of dolutegravir was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed Cτ as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed Cτ of dolutegravir plus S-648414 and dolutegravir alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of dolutegravir were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.3445</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2352</ci_lower_limit>
            <ci_upper_limit>1.4636</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / Dolutegravir</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the plasma PK of dolutegravir was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed Cτ as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed Cτ of dolutegravir plus S-648414 and dolutegravir alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of dolutegravir were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.0769</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0137</ci_lower_limit>
            <ci_upper_limit>1.1441</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / Dolutegravir</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Area Under the Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) for Dolutegravir</title>
        <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.&#xD;
Area under the concentration-time curve over the dosing interval τ (24 hours) was calculated by the linear up/log down trapezoidal method.</description>
        <time_frame>Day 7 and Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: Dolutegravir (100 mg S-648414 Group)</title>
            <description>Participants assigned to the 100 mg S-648414 dose group received 50 mg dolutegravir orally once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: Dolutegravir (200 mg S-648414 Group)</title>
            <description>Participants assigned to the 200 mg S-648414 dose group received 50 mg dolutegravir once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Area Under the Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) for Dolutegravir</title>
          <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.&#xD;
Area under the concentration-time curve over the dosing interval τ (24 hours) was calculated by the linear up/log down trapezoidal method.</description>
          <population>The PK parameter population</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74790" spread="19.7"/>
                    <measurement group_id="O2" value="89290" spread="13.4"/>
                    <measurement group_id="O3" value="69850" spread="20.1"/>
                    <measurement group_id="O4" value="73210" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the plasma PK of dolutegravir was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed AUC0-τ as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed AUC0-τ of dolutegravir plus S-648414 and dolutegravir alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of dolutegravir were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.1939</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1176</ci_lower_limit>
            <ci_upper_limit>1.2754</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / Dolutegravir</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the plasma PK of dolutegravir was assessed using an ANOVA fitted with a linear mixed effect model with the natural log-transformed AUC0-τ as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed AUC0-τ of dolutegravir plus S-648414 and dolutegravir alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, Cτ, and AUC0-τ of dolutegravir were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.0482</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9881</ci_lower_limit>
            <ci_upper_limit>1.1119</ci_upper_limit>
            <estimate_desc>Ratio = S-648414 + Dolutegravir / Dolutegravir</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part 3: Apparent Total Clearance (CL/F) of Dolutegravir</title>
        <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.&#xD;
Apparent total clearance calculated as CL/F =Dose/AUC0-τ</description>
        <time_frame>Day 7 and Day 28 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12 and 24 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3: Dolutegravir (100 mg S-648414 Group)</title>
            <description>Participants assigned to the 100 mg S-648414 dose group received 50 mg dolutegravir orally once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O2">
            <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
          <group group_id="O3">
            <title>Part 3: Dolutegravir (200 mg S-648414 Group)</title>
            <description>Participants assigned to the 200 mg S-648414 dose group received 50 mg dolutegravir once a day on Days 1 to 7.</description>
          </group>
          <group group_id="O4">
            <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
            <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 3: Apparent Total Clearance (CL/F) of Dolutegravir</title>
          <description>The effect of S-648414 on the PK of dolutegravir was assessed after administration of multiple oral doses of dolutegravir alone and after administration of multiple oral doses of S-648414 co-administered with dolutegravir.&#xD;
Apparent total clearance calculated as CL/F =Dose/AUC0-τ</description>
          <population>The PK parameter population</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.669" spread="19.7"/>
                    <measurement group_id="O2" value="0.560" spread="13.4"/>
                    <measurement group_id="O3" value="0.716" spread="20.1"/>
                    <measurement group_id="O4" value="0.683" spread="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Maximum Plasma Concentration (Cmax) of S-648414</title>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Maximum Plasma Concentration (Cmax) of S-648414</title>
          <population>The PK parameter population</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" spread="22.8"/>
                    <measurement group_id="O2" value="498" spread="17.7"/>
                    <measurement group_id="O3" value="1620" spread="13.1"/>
                    <measurement group_id="O4" value="1430" spread="18.0"/>
                    <measurement group_id="O5" value="3820" spread="25.7"/>
                    <measurement group_id="O6" value="9260" spread="31.9"/>
                    <measurement group_id="O7" value="12700" spread="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The dose proportionality of plasma PK parameters of S-648414 was examined for all fasted groups in Part 1 using the power model. The power model assumes a linear relationship between the ln-transformed parameter and ln-transformed dose where ln(Cmax) = Intercept + Slope × ln(Dose) + Random error</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.9857</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9341</ci_lower_limit>
            <ci_upper_limit>1.0373</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of food on the plasma PK of S-648414 was examined after a single dose of 100 mg S-648414 in the fed state and fasted state using an ANOVA fitted with a linear mixed effect model with ln-transformed Cmax as the dependent variable, treatment as a fixed effect, and participant as random effect.&#xD;
The difference and 90% CI between the fed and fasted state ln-transformed Cmax were estimated, then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.8786</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7705</ci_lower_limit>
            <ci_upper_limit>1.0019</ci_upper_limit>
            <estimate_desc>Ratio = Fed / Fasted</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Time to Maximum Plasma Concentration (Tmax) of S-648414</title>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Time to Maximum Plasma Concentration (Tmax) of S-648414</title>
          <population>The PK parameter population</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.25" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O4" value="3.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O5" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O6" value="1.50" lower_limit="1.03" upper_limit="4.00"/>
                    <measurement group_id="O7" value="1.75" lower_limit="1.50" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration After Dosing (AUC0-last) of S-648414</title>
        <description>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing, calculated by the linear trapezoidal method when concentrations are increasing and by the logarithmic trapezoidal method when concentrations are decreasing (linear up/log down trapezoidal method).</description>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration After Dosing (AUC0-last) of S-648414</title>
          <description>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing, calculated by the linear trapezoidal method when concentrations are increasing and by the logarithmic trapezoidal method when concentrations are decreasing (linear up/log down trapezoidal method).</description>
          <population>The PK parameter population</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3431" spread="18.1"/>
                    <measurement group_id="O2" value="10610" spread="19.3"/>
                    <measurement group_id="O3" value="36370" spread="9.2"/>
                    <measurement group_id="O4" value="34910" spread="14.2"/>
                    <measurement group_id="O5" value="89330" spread="20.2"/>
                    <measurement group_id="O6" value="215300" spread="27.1"/>
                    <measurement group_id="O7" value="359300" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The dose proportionality of plasma PK parameters of S-648414 was examined for all fasted groups in Part 1 using the power model. The power model assumes a linear relationship between the ln-transformed parameter and ln-transformed dose where ln(AUC0-last) = Intercept + Slope × ln(Dose) + Random error</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.0252</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9840</ci_lower_limit>
            <ci_upper_limit>1.0665</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of food on the plasma PK of S-648414 was examined after a single dose of 100 mg S-648414 in the fed and fasted state using an ANOVA fitted with a linear mixed effect model, with ln-transformed AUC0-last as the dependent variable, treatment as a fixed effect, and participant as random effect. The difference and 90% CI between the fed and fasted state ln-transformed AUC0-last were estimated, then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.9598</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8585</ci_lower_limit>
            <ci_upper_limit>1.0730</ci_upper_limit>
            <estimate_desc>Ratio = Fed / Fasted</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of S-648414</title>
        <description>Area under the concentration-time curve extrapolated from time zero to infinity defined as AUC0-last + (Clast/λz), where Clast is the last measurable plasma concentration and λz is the plasma terminal elimination rate constant.</description>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of S-648414</title>
          <description>Area under the concentration-time curve extrapolated from time zero to infinity defined as AUC0-last + (Clast/λz), where Clast is the last measurable plasma concentration and λz is the plasma terminal elimination rate constant.</description>
          <population>The PK parameter population</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3620" spread="17.5"/>
                    <measurement group_id="O2" value="11040" spread="19.6"/>
                    <measurement group_id="O3" value="38300" spread="10.9"/>
                    <measurement group_id="O4" value="36940" spread="14.4"/>
                    <measurement group_id="O5" value="95510" spread="21.0"/>
                    <measurement group_id="O6" value="226600" spread="26.5"/>
                    <measurement group_id="O7" value="382000" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>The dose proportionality of plasma PK parameters of S-648414 was examined for all fasted groups in Part 1 using the power model. The power model assumes a linear relationship between the ln-transformed parameter and ln-transformed dose where ln(AUC0-inf) = Intercept + Slope × ln(Dose) + Random error</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>1.0280</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9866</ci_lower_limit>
            <ci_upper_limit>1.0695</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of food on the plasma PK of S-648414 was examined after a single dose of 100 mg S-648414 in the fed and fasted state using an ANOVA fitted with a linear mixed effect model, with ln-transformed AUC0-inf as the dependent variable, treatment as a fixed effect, and participant as random effect. The difference and 90% CI between the fed and fasted state ln-transformed AUC0-inf were estimated, then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.9646</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8643</ci_lower_limit>
            <ci_upper_limit>1.0766</ci_upper_limit>
            <estimate_desc>Ratio = Fed / Fasted</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Terminal Elimination Half-life (t1/2,z) of S-648414</title>
        <description>Terminal elimination half-life calculated as t1/2,z = (ln2)/λz, where λz is the terminal elimination rate constant.</description>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Terminal Elimination Half-life (t1/2,z) of S-648414</title>
          <description>Terminal elimination half-life calculated as t1/2,z = (ln2)/λz, where λz is the terminal elimination rate constant.</description>
          <population>The PK parameter population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="5.0"/>
                    <measurement group_id="O2" value="20.7" spread="9.9"/>
                    <measurement group_id="O3" value="22.2" spread="16.0"/>
                    <measurement group_id="O4" value="22.8" spread="14.2"/>
                    <measurement group_id="O5" value="24.1" spread="12.1"/>
                    <measurement group_id="O6" value="22.2" spread="12.1"/>
                    <measurement group_id="O7" value="23.7" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of food on the plasma PK of S-648414 was examined after a single dose of 100 mg S-648414 in the fed and fasted state using an ANOVA fitted with a linear mixed effect model, with ln-transformed t1/2,z as the dependent variable, treatment as a fixed effect, and participant as random effect. The difference and 90% CI between the fed and fasted state ln-transformed t1/2,z were estimated, then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.0272</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9949</ci_lower_limit>
            <ci_upper_limit>1.0606</ci_upper_limit>
            <estimate_desc>Ratio = Fed / Fasted</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Terminal Elimination Rate Constant (λz) of S-648414</title>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Terminal Elimination Rate Constant (λz) of S-648414</title>
          <population>The PK parameter population</population>
          <units>1/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0301" spread="5.0"/>
                    <measurement group_id="O2" value="0.0336" spread="9.9"/>
                    <measurement group_id="O3" value="0.0313" spread="16.0"/>
                    <measurement group_id="O4" value="0.0305" spread="14.2"/>
                    <measurement group_id="O5" value="0.0288" spread="12.1"/>
                    <measurement group_id="O6" value="0.0312" spread="12.1"/>
                    <measurement group_id="O7" value="0.0293" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Mean Residence Time (MRT) of S-648414</title>
        <description>Mean residence time, calculated as MRT = AUMC0-inf / AUC0-inf, where AUMC0-inf is the area under the first moment curve extrapolated to infinity.</description>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Mean Residence Time (MRT) of S-648414</title>
          <description>Mean residence time, calculated as MRT = AUMC0-inf / AUC0-inf, where AUMC0-inf is the area under the first moment curve extrapolated to infinity.</description>
          <population>The PK parameter population</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="4.3"/>
                    <measurement group_id="O2" value="29.2" spread="9.5"/>
                    <measurement group_id="O3" value="31.5" spread="16.1"/>
                    <measurement group_id="O4" value="33.8" spread="14.6"/>
                    <measurement group_id="O5" value="34.2" spread="12.6"/>
                    <measurement group_id="O6" value="32.6" spread="12.9"/>
                    <measurement group_id="O7" value="34.5" spread="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Apparent Total Clearance (CL/F) of S-648414</title>
        <description>Apparent total clearance estimated according to: CL/F = Dose / AUC0-inf.</description>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent Total Clearance (CL/F) of S-648414</title>
          <description>Apparent total clearance estimated according to: CL/F = Dose / AUC0-inf.</description>
          <population>The PK parameter population</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.76" spread="17.5"/>
                    <measurement group_id="O2" value="2.72" spread="19.6"/>
                    <measurement group_id="O3" value="2.61" spread="10.9"/>
                    <measurement group_id="O4" value="2.71" spread="14.4"/>
                    <measurement group_id="O5" value="2.62" spread="21.0"/>
                    <measurement group_id="O6" value="2.21" spread="26.5"/>
                    <measurement group_id="O7" value="2.62" spread="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Apparent Volume of Distribution in the Terminal Elimination Phase (Vz/F) of S-648414</title>
        <description>Apparent volume of distribution in the terminal elimination phase was estimated according to: Vz /F = Dose / AUC0-inf / λz.</description>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72 and 96 hours postdose.</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Apparent Volume of Distribution in the Terminal Elimination Phase (Vz/F) of S-648414</title>
          <description>Apparent volume of distribution in the terminal elimination phase was estimated according to: Vz /F = Dose / AUC0-inf / λz.</description>
          <population>The PK parameter population</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" spread="21.2"/>
                    <measurement group_id="O2" value="81.0" spread="21.2"/>
                    <measurement group_id="O3" value="83.5" spread="11.0"/>
                    <measurement group_id="O4" value="88.9" spread="19.5"/>
                    <measurement group_id="O5" value="91.0" spread="17.3"/>
                    <measurement group_id="O6" value="70.8" spread="31.7"/>
                    <measurement group_id="O7" value="89.3" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Fraction of S-648414 Dose Excreted in Urine From 0 to 96 Hours Postdose (Feu0-96)</title>
        <description>The fraction of S-648414 dose excreted in urine from 0 to 96 hours postdose was calculated as:&#xD;
Cumulative amount of S-648414 excreted in urine from time zero to 96 hours postdose (Aeu0-96) / Dose × 100</description>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose (-12 to 0 hours), 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours postdose</time_frame>
        <population>The PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Fraction of S-648414 Dose Excreted in Urine From 0 to 96 Hours Postdose (Feu0-96)</title>
          <description>The fraction of S-648414 dose excreted in urine from 0 to 96 hours postdose was calculated as:&#xD;
Cumulative amount of S-648414 excreted in urine from time zero to 96 hours postdose (Aeu0-96) / Dose × 100</description>
          <population>The PK parameter population</population>
          <units>percent excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="22.6"/>
                    <measurement group_id="O2" value="25.5" spread="20.1"/>
                    <measurement group_id="O3" value="25.3" spread="19.2"/>
                    <measurement group_id="O4" value="25.1" spread="11.1"/>
                    <measurement group_id="O5" value="28.7" spread="19.8"/>
                    <measurement group_id="O6" value="31.5" spread="10.2"/>
                    <measurement group_id="O7" value="25.9" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Renal Clearance (CLR) of S-648414</title>
        <description>Renal clearance was estimated according to: CLR = cumulative amount of S-648414 excreted in urine from time zero to 96 hours postdose (Aeu0-96) / area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last).</description>
        <time_frame>Day 1 and Day 14 (for participants in the 100 mg dose group only) predose (-12 to 0 hours), 0 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours postdose</time_frame>
        <population>PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414 Fasted</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414 Fed</title>
            <description>Participants received a single dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Renal Clearance (CLR) of S-648414</title>
          <description>Renal clearance was estimated according to: CLR = cumulative amount of S-648414 excreted in urine from time zero to 96 hours postdose (Aeu0-96) / area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last).</description>
          <population>PK parameter population</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.884" spread="11.6"/>
                    <measurement group_id="O2" value="0.721" spread="25.9"/>
                    <measurement group_id="O3" value="0.695" spread="17.5"/>
                    <measurement group_id="O4" value="0.720" spread="18.4"/>
                    <measurement group_id="O5" value="0.804" spread="10.3"/>
                    <measurement group_id="O6" value="0.732" spread="30.6"/>
                    <measurement group_id="O7" value="0.720" spread="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Maximum Plasma Concentration (Cmax) of S-648414 Following Single and Multiple-dose Administration</title>
        <time_frame>Day 1 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose; Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
        <population>The PK parameter population with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Maximum Plasma Concentration (Cmax) of S-648414 Following Single and Multiple-dose Administration</title>
          <population>The PK parameter population with available data at each time point</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="411" spread="22.3"/>
                    <measurement group_id="O2" value="623" spread="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="719" spread="13.2"/>
                    <measurement group_id="O2" value="1320" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The dose proportionality of plasma S-648414 Cmax after a single dose of S-648414 (Day 1) was assessed using an ANOVA model fitted to the ln-transformed Cmax, with dose group fitted as a fixed factor.&#xD;
The point estimates and 90% CIs were generated for the ratios of the 50 mg dose to 30 mg dose ln-transformed Cmax, then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.5167</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2654</ci_lower_limit>
            <ci_upper_limit>1.8180</ci_upper_limit>
            <estimate_desc>Ratio = 50 mg / 30 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The dose proportionality of plasma S-648414 Cmax after multiple doses of S-648414 (Day 14) was assessed using an ANOVA model fitted to the ln-transformed Cmax, with dose group fitted as a fixed factor.&#xD;
The point estimates and 90% CIs were generated for the ratios of the 50 mg dose to 30 mg dose ln-transformed Cmax, then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.8372</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5696</ci_lower_limit>
            <ci_upper_limit>2.1506</ci_upper_limit>
            <estimate_desc>Ratio = 50 mg / 30 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The accumulation ratio of Cmax in the 30 mg dose group was calculated as the ratio of Day 14 to Day 1 using an ANOVA fitted with a linear mixed model with ln-transformed Cmax, Day as a fixed effect and participant as a random effect.&#xD;
The difference and 90% CI between the ln-transformed Cmax on Day 1 and Day 14 were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.7489</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5250</ci_lower_limit>
            <ci_upper_limit>2.0057</ci_upper_limit>
            <estimate_desc>Ratio = Day 14 / Day 1</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The accumulation ratio of Cmax in the 50 mg dose group was calculated as the ratio of Day 14 to Day 1 using an ANOVA fitted with a linear mixed model with ln-transformed Cmax, Day as a fixed effect and participant as a random effect.&#xD;
The difference and 90% CI between the ln-transformed Cmax on Day 1 and Day 14 were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>2.1453</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9741</ci_lower_limit>
            <ci_upper_limit>2.3313</ci_upper_limit>
            <estimate_desc>Ratio = Day 14 / Day 1</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Time to Maximum Plasma Concentration (Tmax) of S-648414 Following Single and Multiple-dose Administration</title>
        <time_frame>Day 1 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose; Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
        <population>The PK parameter population with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Time to Maximum Plasma Concentration (Tmax) of S-648414 Following Single and Multiple-dose Administration</title>
          <population>The PK parameter population with available data at each time point</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.02" lower_limit="2.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="4.50" lower_limit="2.50" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" lower_limit="1.50" upper_limit="5.12"/>
                    <measurement group_id="O2" value="1.25" lower_limit="1.00" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Area Under the Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) of S-648414 Following Single and Multiple-dose Administration</title>
        <description>Area under the concentration-time curve over the dosing interval (24 hours) on Day 1 and Day 14, calculated by the linear up/log down trapezoidal method.</description>
        <time_frame>Day 1 and day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Concentration-time Curve Over the Dosing Interval τ (AUC0-τ) of S-648414 Following Single and Multiple-dose Administration</title>
          <description>Area under the concentration-time curve over the dosing interval (24 hours) on Day 1 and Day 14, calculated by the linear up/log down trapezoidal method.</description>
          <population>The PK parameter population with available data at each time point</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5519" spread="15.9"/>
                    <measurement group_id="O2" value="8983" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10540" spread="14.9"/>
                    <measurement group_id="O2" value="18400" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The dose proportionality of plasma S-648414 AUC0-τ after a single dose of S-648414 (Day 1) was assessed using an ANOVA model fitted to the ln-transformed AUC0-τ, with dose group fitted as a fixed factor.&#xD;
The point estimates and 90% CIs were generated for the ratios of the 50 mg dose to 30 mg dose ln-transformed AUC0-τ, then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.6277</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4038</ci_lower_limit>
            <ci_upper_limit>1.8874</ci_upper_limit>
            <estimate_desc>Ratio = 50 mg / 30 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The dose proportionality of plasma S-648414 AUC0-τ after multiple doses of S-648414 (Day 14) was assessed using an ANOVA model fitted to the ln-transformed AUC0-τ, with dose group fitted as a fixed factor.&#xD;
The point estimates and 90% CIs were generated for the ratios of the 50 mg dose to 30 mg dose ln-transformed AUC0-τ, then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.7454</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4785</ci_lower_limit>
            <ci_upper_limit>2.0605</ci_upper_limit>
            <estimate_desc>Ratio = 50 mg / 30 mg</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The accumulation ratio of AUC0-τ in the 30 mg dose group was calculated as the ratio of Day 14 to Day 1 using an ANOVA fitted with a linear mixed model with ln-transformed AUC0-τ, Day as a fixed effect and participant as a random effect.&#xD;
The difference and 90% CI between the ln-transformed AUC0-τ on Day 1 and Day 14 were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.9102</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.7788</ci_lower_limit>
            <ci_upper_limit>2.0513</ci_upper_limit>
            <estimate_desc>Ratio = Day 14 / Day 1</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The accumulation ratio of AUC0-τ in the 50 mg dose group was calculated as the ratio of Day 14 to Day 1 using an ANOVA fitted with a linear mixed model with ln-transformed AUC0-τ, Day as a fixed effect and participant as a random effect.&#xD;
The difference and 90% CI between the ln-transformed AUC0-τ on Day 1 and Day 14 were estimated then back-transformed to obtain the corresponding geometric least squares mean ratio and 90% CI.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>2.0478</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9203</ci_lower_limit>
            <ci_upper_limit>2.1837</ci_upper_limit>
            <estimate_desc>Ratio = Day 14 / Day 1</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Terminal Elimination Half-life (t1/2,z) of S-648414 Following Multiple-dose Administration</title>
        <description>Terminal elimination half-life, where t1/2,z = (ln2)/λz on Day 14.</description>
        <time_frame>Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Terminal Elimination Half-life (t1/2,z) of S-648414 Following Multiple-dose Administration</title>
          <description>Terminal elimination half-life, where t1/2,z = (ln2)/λz on Day 14.</description>
          <population>The PK parameter population with available data</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="12.5"/>
                    <measurement group_id="O2" value="23.7" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Terminal Elimination Rate Constant (λz) of S-648414 Following Multiple-dose Administration</title>
        <description>Terminal elimination rate constant, where λz is the magnitude of the slope of the linear regression of the log concentration versus time profile during the terminal phase on Day 14.</description>
        <time_frame>Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Terminal Elimination Rate Constant (λz) of S-648414 Following Multiple-dose Administration</title>
          <description>Terminal elimination rate constant, where λz is the magnitude of the slope of the linear regression of the log concentration versus time profile during the terminal phase on Day 14.</description>
          <population>The PK parameter population with available data</population>
          <units>1/hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0321" spread="12.5"/>
                    <measurement group_id="O2" value="0.0292" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Total Clearance (CL/F) of S-648414 Following Multiple-dose Administration</title>
        <description>Apparent total clearance estimated according to: CL/F = Dose/AUC0-τ on Day 14</description>
        <time_frame>Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Total Clearance (CL/F) of S-648414 Following Multiple-dose Administration</title>
          <description>Apparent total clearance estimated according to: CL/F = Dose/AUC0-τ on Day 14</description>
          <population>The PK parameter population with available data</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" spread="14.9"/>
                    <measurement group_id="O2" value="2.72" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Apparent Volume of Distribution in the Terminal Elimination Phase (Vz/F) of S-648414 Following Multiple-dose Administration</title>
        <description>Apparent volume of distribution in the terminal elimination phase on Day 14, estimated according to: Vz /F = Dose/AUC0-τ/λz</description>
        <time_frame>Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, and 96 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Apparent Volume of Distribution in the Terminal Elimination Phase (Vz/F) of S-648414 Following Multiple-dose Administration</title>
          <description>Apparent volume of distribution in the terminal elimination phase on Day 14, estimated according to: Vz /F = Dose/AUC0-τ/λz</description>
          <population>The PK parameter population with available data</population>
          <units>liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" spread="13.6"/>
                    <measurement group_id="O2" value="93.0" spread="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Fraction of S-648414 Dose Excreted in Urine Over the Dosing Interval (Feu0- τ) Following Multiple-dose Administration</title>
        <description>Fraction of dose excreted in urine over the dosing interval τ (24 hours) on Day 14 calculated as Aeu0-τ/Dose × 100, where Aeu0-τ is the amount of drug excreted in urine over the dosing interval τ (24 hours).</description>
        <time_frame>Day 14 0-24 hours postdose</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Fraction of S-648414 Dose Excreted in Urine Over the Dosing Interval (Feu0- τ) Following Multiple-dose Administration</title>
          <description>Fraction of dose excreted in urine over the dosing interval τ (24 hours) on Day 14 calculated as Aeu0-τ/Dose × 100, where Aeu0-τ is the amount of drug excreted in urine over the dosing interval τ (24 hours).</description>
          <population>The PK parameter population with available data</population>
          <units>percent excreted</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="15.7"/>
                    <measurement group_id="O2" value="35.0" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Renal Clearance (CLR) of S-648414 Following Multiple-dose Administration</title>
        <description>Renal clearance on Day 14, calculated as CLR = Aeu0-τ/AUC0-τ, where Aeu0-τ is the amount of drug excreted in urine over the dosing interval τ (24 hours)</description>
        <time_frame>Day 14 0-24 hours postdose</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 once a day on Days 1 to 14 and a single oral dose of 5 mg midazolam alone on Day -2 and co-administered with the S-648414 dose on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Renal Clearance (CLR) of S-648414 Following Multiple-dose Administration</title>
          <description>Renal clearance on Day 14, calculated as CLR = Aeu0-τ/AUC0-τ, where Aeu0-τ is the amount of drug excreted in urine over the dosing interval τ (24 hours)</description>
          <population>The PK parameter population with available data</population>
          <units>L/hr</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.948" spread="18.4"/>
                    <measurement group_id="O2" value="0.952" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Maximum Plasma Concentration (Cmax) of Midazolam</title>
        <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
        <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Midazolam (30 mg S-648414 Group)</title>
            <description>Participants assigned to the 30 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Midazolam (50 mg S-648414 Group)</title>
            <description>Participants assigned to the 50 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Maximum Plasma Concentration (Cmax) of Midazolam</title>
          <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
          <population>The PK parameter population with available data</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" spread="33.6"/>
                    <measurement group_id="O2" value="16.8" spread="25.6"/>
                    <measurement group_id="O3" value="19.5" spread="30.6"/>
                    <measurement group_id="O4" value="19.3" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the PK of midazolam (a CYP3A substrate) was assessed using an ANOVA fitted with a linear mixed effect model with ln-transformed Cmax as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed Cmax of midazolam plus S-648414 and midazolam alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratios and 90% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, AUC0-last, and AUC0-inf of midazolam were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.9241</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8057</ci_lower_limit>
            <ci_upper_limit>1.0600</ci_upper_limit>
            <estimate_desc>Ratio = 30 mg S-648414 + Midazolam / Midazolam</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the PK of midazolam (a CYP3A substrate) was assessed using an ANOVA fitted with a linear mixed effect model with ln-transformed Cmax as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed Cmax of midazolam plus S-648414 and midazolam alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratios and 90% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, AUC0-last, and AUC0-inf of midazolam were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>1.0303</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9299</ci_lower_limit>
            <ci_upper_limit>1.1415</ci_upper_limit>
            <estimate_desc>Ratio = 50 mg S-648414 + Midazolam / Midazolam</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Time to Maximum Plasma Concentration of Midazolam</title>
        <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
        <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Midazolam (30 mg S-648414 Group)</title>
            <description>Participants assigned to the 30 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Midazolam (50 mg S-648414 Group)</title>
            <description>Participants assigned to the 50 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Time to Maximum Plasma Concentration of Midazolam</title>
          <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
          <population>The PK parameter population with available data</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" lower_limit="0.50" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.50" upper_limit="2.08"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.50" lower_limit="0.50" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration After Dosing (AUC0-last) for Midazolam</title>
        <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).&#xD;
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing, calculated by linear up/log down trapezoidal method.</description>
        <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Midazolam (30 mg S-648414 Group)</title>
            <description>Participants assigned to the 30 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Midazolam (50 mg S-648414 Group)</title>
            <description>Participants assigned to the 50 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration After Dosing (AUC0-last) for Midazolam</title>
          <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).&#xD;
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing, calculated by linear up/log down trapezoidal method.</description>
          <population>The PK parameter population with available data</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.17" spread="30.7"/>
                    <measurement group_id="O2" value="59.83" spread="40.5"/>
                    <measurement group_id="O3" value="73.28" spread="40.7"/>
                    <measurement group_id="O4" value="64.53" spread="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the PK of midazolam (a CYP3A substrate) was assessed using an ANOVA fitted with a linear mixed effect model with ln-transformed AUC0-last as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed AUC0-last of midazolam plus S-648414 and midazolam alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratios and 90% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, AUC0-last, and AUC0-inf of midazolam were completely contained within the range of 0.8000 to 1.2500</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.8420</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6628</ci_lower_limit>
            <ci_upper_limit>1.0696</ci_upper_limit>
            <estimate_desc>Ratio = 30 mg S-648414 + Midazolam / Midazolam</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the PK of midazolam (a CYP3A substrate) was assessed using an ANOVA fitted with a linear mixed effect model with ln-transformed AUC0-last as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed AUC0-last of midazolam plus S-648414 and midazolam alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratios and 90% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, AUC0-last, and AUC0-inf of midazolam were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.8542</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7185</ci_lower_limit>
            <ci_upper_limit>1.0155</ci_upper_limit>
            <estimate_desc>Ratio = 50 mg S-648414 + Midazolam / Midazolam</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam</title>
        <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).&#xD;
Area under the concentration-time curve extrapolated from time zero to infinity defined as AUC0-last + (Clast/λz), where Clast is the last measurable plasma concentration and λz is the plasma terminal elimination rate constant.</description>
        <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Midazolam (30 mg S-648414 Group)</title>
            <description>Participants assigned to the 30 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Midazolam (50 mg S-648414 Group)</title>
            <description>Participants assigned to the 50 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of Midazolam</title>
          <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).&#xD;
Area under the concentration-time curve extrapolated from time zero to infinity defined as AUC0-last + (Clast/λz), where Clast is the last measurable plasma concentration and λz is the plasma terminal elimination rate constant.</description>
          <population>The PK parameter population with available data</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.81" spread="28.7"/>
                    <measurement group_id="O2" value="61.68" spread="41.2"/>
                    <measurement group_id="O3" value="76.03" spread="42.2"/>
                    <measurement group_id="O4" value="67.02" spread="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the PK of midazolam (a CYP3A substrate) was assessed using an ANOVA fitted with a linear mixed effect model with ln-transformed AUC0-inf as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed AUC0-inf of midazolam plus S-648414 and midazolam alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratios and 90% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, AUC0-last, and AUC0-inf of midazolam were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.8377</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6645</ci_lower_limit>
            <ci_upper_limit>1.0561</ci_upper_limit>
            <estimate_desc>Ratio = 30 mg S-648414 + Midazolam / Midazolam</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The effect of S-648414 on the PK of midazolam (a CYP3A substrate) was assessed using an ANOVA fitted with a linear mixed effect model with ln-transformed AUC0-inf as the dependent variable, treatment as a fixed effect, and participant as a random effect. The difference and 90% CI between the ln-transformed AUC0-inf of midazolam plus S-648414 and midazolam alone was estimated then back-transformed to obtain the corresponding geometric least squares mean ratios and 90% CIs.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The drug interaction was assessed by whether the 90% CIs for the geometric least squares mean ratio of Cmax, AUC0-last, and AUC0-inf of midazolam were completely contained within the range of 0.8000 to 1.2500.</non_inferiority_desc>
            <param_type>Geometric Least Squares Mean Ratio</param_type>
            <param_value>0.8529</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7213</ci_lower_limit>
            <ci_upper_limit>1.0085</ci_upper_limit>
            <estimate_desc>Ratio = 50 mg S-648414 + Midazolam / Midazolam</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Terminal Elimination Half-life for Midazolam</title>
        <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
        <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Midazolam (30 mg S-648414 Group)</title>
            <description>Participants assigned to the 30 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Midazolam (50 mg S-648414 Group)</title>
            <description>Participants assigned to the 50 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Terminal Elimination Half-life for Midazolam</title>
          <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
          <population>The PK parameter population with available data</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.07" spread="18.7"/>
                    <measurement group_id="O2" value="4.64" spread="32.4"/>
                    <measurement group_id="O3" value="4.41" spread="41.1"/>
                    <measurement group_id="O4" value="4.54" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Terminal Elimination Rate Constant for Midazolam</title>
        <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
        <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Midazolam (30 mg S-648414 Group)</title>
            <description>Participants assigned to the 30 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Midazolam (50 mg S-648414 Group)</title>
            <description>Participants assigned to the 50 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Terminal Elimination Rate Constant for Midazolam</title>
          <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).</description>
          <population>The PK parameter population with available data</population>
          <units>1/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1366" spread="18.7"/>
                    <measurement group_id="O2" value="0.1494" spread="32.4"/>
                    <measurement group_id="O3" value="0.1570" spread="41.1"/>
                    <measurement group_id="O4" value="0.1528" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2: Mean Residence Time for Midazolam</title>
        <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).&#xD;
Mean residence time was calculated as MRT = AUMC0-inf/AUC0-inf where AUMC0-inf is the area under the first moment curve extrapolated to infinity.</description>
        <time_frame>Day -2 and Day 14 predose (0 hours), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The PK parameter population with available data</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: Midazolam (30 mg S-648414 Group)</title>
            <description>Participants assigned to the 30 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O2">
            <title>Part 2: 30 mg S-648414 + Midazolam</title>
            <description>Participants received 30 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: Midazolam (50 mg S-648414 Group)</title>
            <description>Participants assigned to the 50 mg S-648414 dose group received a single oral dose of 5 mg midazolam on Day -2</description>
          </group>
          <group group_id="O4">
            <title>Part 2: 50 mg S-648414 + Midazolam</title>
            <description>Participants received 50 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2: Mean Residence Time for Midazolam</title>
          <description>The effect of S-648414 on the PK of midazolam (a cytochrome P450 3A [CYP3A] substrate) was assessed in Part 2 following 5 mg midazolam administration alone (Day -2) and co-administration with S-648414 30 or 50 mg (Day 14).&#xD;
Mean residence time was calculated as MRT = AUMC0-inf/AUC0-inf where AUMC0-inf is the area under the first moment curve extrapolated to infinity.</description>
          <population>The PK parameter population with available data</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.30" spread="8.6"/>
                    <measurement group_id="O2" value="4.44" spread="28.3"/>
                    <measurement group_id="O3" value="4.93" spread="33.8"/>
                    <measurement group_id="O4" value="4.40" spread="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in Fridericia's Corrected QT Interval (QTcF)</title>
        <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. The QT interval is a measure between Q and T wave in heart's electrical cycle. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
QT interval was corrected for heart rate using Fridericia's correction (QTcF). Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔQTcF) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QTcF as covariate.</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The QT/QTc population included all study participants randomly assigned to study intervention and who took at least 1 dose of study intervention.who had measurements at Baseline as well as on-treatment, with at least 1 post-dose time point with a valid ΔQTcF value. Participants with available data at each time point are included. Cardiodynamic ECG assessments were performed for Part 1 only.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participants received a single oral dose of matching placebo in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in Fridericia's Corrected QT Interval (QTcF)</title>
          <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. The QT interval is a measure between Q and T wave in heart's electrical cycle. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
QT interval was corrected for heart rate using Fridericia's correction (QTcF). Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔQTcF) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QTcF as covariate.</description>
          <population>The QT/QTc population included all study participants randomly assigned to study intervention and who took at least 1 dose of study intervention.who had measurements at Baseline as well as on-treatment, with at least 1 post-dose time point with a valid ΔQTcF value. Participants with available data at each time point are included. Cardiodynamic ECG assessments were performed for Part 1 only.</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="1.16"/>
                    <measurement group_id="O2" value="-3.2" spread="1.61"/>
                    <measurement group_id="O3" value="-5.6" spread="1.61"/>
                    <measurement group_id="O4" value="-4.8" spread="1.40"/>
                    <measurement group_id="O5" value="-4.1" spread="1.64"/>
                    <measurement group_id="O6" value="-5.6" spread="1.69"/>
                    <measurement group_id="O7" value="2.0" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="1.19"/>
                    <measurement group_id="O2" value="-0.4" spread="1.66"/>
                    <measurement group_id="O3" value="-2.4" spread="1.66"/>
                    <measurement group_id="O4" value="-3.2" spread="1.44"/>
                    <measurement group_id="O5" value="-0.9" spread="1.69"/>
                    <measurement group_id="O6" value="-1.0" spread="1.74"/>
                    <measurement group_id="O7" value="4.9" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.40"/>
                    <measurement group_id="O2" value="-1.2" spread="1.96"/>
                    <measurement group_id="O3" value="-2.6" spread="1.96"/>
                    <measurement group_id="O4" value="-1.1" spread="1.69"/>
                    <measurement group_id="O5" value="1.8" spread="1.98"/>
                    <measurement group_id="O6" value="3.1" spread="2.02"/>
                    <measurement group_id="O7" value="4.9" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.38"/>
                    <measurement group_id="O2" value="-2.1" spread="1.93"/>
                    <measurement group_id="O3" value="-1.0" spread="1.93"/>
                    <measurement group_id="O4" value="-1.9" spread="1.67"/>
                    <measurement group_id="O5" value="-1.2" spread="1.95"/>
                    <measurement group_id="O6" value="2.4" spread="1.99"/>
                    <measurement group_id="O7" value="6.3" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="1.39"/>
                    <measurement group_id="O2" value="-1.7" spread="1.94"/>
                    <measurement group_id="O3" value="-1.5" spread="1.94"/>
                    <measurement group_id="O4" value="-1.1" spread="1.68"/>
                    <measurement group_id="O5" value="0.4" spread="1.97"/>
                    <measurement group_id="O6" value="2.5" spread="2.01"/>
                    <measurement group_id="O7" value="8.0" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="1.24"/>
                    <measurement group_id="O2" value="2.3" spread="1.73"/>
                    <measurement group_id="O3" value="-1.3" spread="1.73"/>
                    <measurement group_id="O4" value="-0.6" spread="1.50"/>
                    <measurement group_id="O5" value="2.6" spread="1.76"/>
                    <measurement group_id="O6" value="-0.4" spread="1.80"/>
                    <measurement group_id="O7" value="10.1" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="1.54"/>
                    <measurement group_id="O2" value="-0.2" spread="2.16"/>
                    <measurement group_id="O3" value="-0.6" spread="2.16"/>
                    <measurement group_id="O4" value="0.1" spread="1.87"/>
                    <measurement group_id="O5" value="0.2" spread="2.18"/>
                    <measurement group_id="O6" value="3.6" spread="2.22"/>
                    <measurement group_id="O7" value="12.0" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="2.52"/>
                    <measurement group_id="O2" value="-12.0" spread="3.55"/>
                    <measurement group_id="O3" value="-2.3" spread="3.56"/>
                    <measurement group_id="O4" value="-1.2" spread="3.08"/>
                    <measurement group_id="O5" value="-4.6" spread="3.57"/>
                    <measurement group_id="O6" value="-4.6" spread="3.59"/>
                    <measurement group_id="O7" value="2.9" spread="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="1.71"/>
                    <measurement group_id="O2" value="-6.7" spread="2.41"/>
                    <measurement group_id="O3" value="-0.3" spread="2.41"/>
                    <measurement group_id="O4" value="-3.2" spread="2.08"/>
                    <measurement group_id="O5" value="-5.9" spread="2.43"/>
                    <measurement group_id="O6" value="-3.4" spread="2.46"/>
                    <measurement group_id="O7" value="5.0" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.44"/>
                    <measurement group_id="O2" value="-1.8" spread="3.44"/>
                    <measurement group_id="O3" value="0.9" spread="3.44"/>
                    <measurement group_id="O4" value="1.0" spread="2.98"/>
                    <measurement group_id="O5" value="-1.3" spread="3.45"/>
                    <measurement group_id="O6" value="-3.0" spread="3.48"/>
                    <measurement group_id="O7" value="8.8" spread="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.19"/>
                    <measurement group_id="O2" value="-4.9" spread="1.66"/>
                    <measurement group_id="O3" value="-1.2" spread="1.66"/>
                    <measurement group_id="O4" value="-2.1" spread="1.44"/>
                    <measurement group_id="O5" value="-0.8" spread="1.69"/>
                    <measurement group_id="O6" value="-1.8" spread="1.74"/>
                    <measurement group_id="O7" value="7.5" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parts 1: Change From Baseline in Heart Rate (HR)</title>
        <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median HR in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG values from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in HR (ΔHR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline HR as covariate.</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The QT/QTc population with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participants received a single oral dose of matching placebo in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Parts 1: Change From Baseline in Heart Rate (HR)</title>
          <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median HR in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG values from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in HR (ΔHR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline HR as covariate.</description>
          <population>The QT/QTc population with available data at each time point</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.11"/>
                    <measurement group_id="O2" value="-0.2" spread="1.58"/>
                    <measurement group_id="O3" value="-1.4" spread="1.60"/>
                    <measurement group_id="O4" value="-1.1" spread="1.36"/>
                    <measurement group_id="O5" value="-0.1" spread="1.57"/>
                    <measurement group_id="O6" value="-0.7" spread="1.57"/>
                    <measurement group_id="O7" value="-1.6" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.16"/>
                    <measurement group_id="O2" value="-2.7" spread="1.64"/>
                    <measurement group_id="O3" value="-1.9" spread="1.66"/>
                    <measurement group_id="O4" value="-2.1" spread="1.41"/>
                    <measurement group_id="O5" value="0.4" spread="1.64"/>
                    <measurement group_id="O6" value="-1.0" spread="1.63"/>
                    <measurement group_id="O7" value="-0.8" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.18"/>
                    <measurement group_id="O2" value="-3.0" spread="1.67"/>
                    <measurement group_id="O3" value="-0.3" spread="1.69"/>
                    <measurement group_id="O4" value="-3.0" spread="1.44"/>
                    <measurement group_id="O5" value="-0.5" spread="1.67"/>
                    <measurement group_id="O6" value="0.2" spread="1.67"/>
                    <measurement group_id="O7" value="-0.4" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.30"/>
                    <measurement group_id="O2" value="-3.2" spread="1.85"/>
                    <measurement group_id="O3" value="-2.4" spread="1.87"/>
                    <measurement group_id="O4" value="-2.5" spread="1.60"/>
                    <measurement group_id="O5" value="-1.7" spread="1.85"/>
                    <measurement group_id="O6" value="0.4" spread="1.85"/>
                    <measurement group_id="O7" value="-0.3" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.28"/>
                    <measurement group_id="O2" value="-1.2" spread="1.82"/>
                    <measurement group_id="O3" value="-3.0" spread="1.84"/>
                    <measurement group_id="O4" value="-2.2" spread="1.57"/>
                    <measurement group_id="O5" value="-0.7" spread="1.81"/>
                    <measurement group_id="O6" value="2.7" spread="1.81"/>
                    <measurement group_id="O7" value="-0.7" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.38"/>
                    <measurement group_id="O2" value="-3.0" spread="1.96"/>
                    <measurement group_id="O3" value="-1.6" spread="1.97"/>
                    <measurement group_id="O4" value="-2.1" spread="1.69"/>
                    <measurement group_id="O5" value="-1.8" spread="1.95"/>
                    <measurement group_id="O6" value="2.0" spread="1.95"/>
                    <measurement group_id="O7" value="-0.6" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.41"/>
                    <measurement group_id="O2" value="-1.2" spread="2.00"/>
                    <measurement group_id="O3" value="0.7" spread="2.02"/>
                    <measurement group_id="O4" value="-2.8" spread="1.73"/>
                    <measurement group_id="O5" value="0.8" spread="2.00"/>
                    <measurement group_id="O6" value="2.1" spread="2.00"/>
                    <measurement group_id="O7" value="3.3" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="1.18"/>
                    <measurement group_id="O2" value="4.6" spread="1.68"/>
                    <measurement group_id="O3" value="2.4" spread="1.70"/>
                    <measurement group_id="O4" value="4.2" spread="1.45"/>
                    <measurement group_id="O5" value="3.7" spread="1.67"/>
                    <measurement group_id="O6" value="7.3" spread="1.67"/>
                    <measurement group_id="O7" value="7.5" spread="1.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.56"/>
                    <measurement group_id="O2" value="1.7" spread="2.21"/>
                    <measurement group_id="O3" value="0.7" spread="2.22"/>
                    <measurement group_id="O4" value="-0.2" spread="1.91"/>
                    <measurement group_id="O5" value="1.8" spread="2.20"/>
                    <measurement group_id="O6" value="4.6" spread="2.20"/>
                    <measurement group_id="O7" value="3.5" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="1.80"/>
                    <measurement group_id="O2" value="1.1" spread="2.55"/>
                    <measurement group_id="O3" value="1.9" spread="2.56"/>
                    <measurement group_id="O4" value="1.1" spread="2.21"/>
                    <measurement group_id="O5" value="2.4" spread="2.55"/>
                    <measurement group_id="O6" value="9.1" spread="2.55"/>
                    <measurement group_id="O7" value="3.4" spread="2.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.64"/>
                    <measurement group_id="O2" value="-1.7" spread="2.33"/>
                    <measurement group_id="O3" value="-0.4" spread="2.34"/>
                    <measurement group_id="O4" value="-1.4" spread="2.01"/>
                    <measurement group_id="O5" value="0.8" spread="2.33"/>
                    <measurement group_id="O6" value="0.3" spread="2.32"/>
                    <measurement group_id="O7" value="3.3" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in PR Interval</title>
        <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. The PR interval is the time from the onset of the P-wave to the start of the next QRS complex. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median PR in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in PR interval (ΔPR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline PR as covariate.</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The QT/QTc population with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participants received a single oral dose of matching placebo in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in PR Interval</title>
          <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. The PR interval is the time from the onset of the P-wave to the start of the next QRS complex. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median PR in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in PR interval (ΔPR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline PR as covariate.</description>
          <population>The QT/QTc population with available data at each time point</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.29"/>
                    <measurement group_id="O2" value="1.0" spread="1.87"/>
                    <measurement group_id="O3" value="2.2" spread="1.83"/>
                    <measurement group_id="O4" value="-0.1" spread="1.61"/>
                    <measurement group_id="O5" value="1.3" spread="1.85"/>
                    <measurement group_id="O6" value="-3.9" spread="1.84"/>
                    <measurement group_id="O7" value="0.0" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.29"/>
                    <measurement group_id="O2" value="1.0" spread="1.86"/>
                    <measurement group_id="O3" value="4.0" spread="1.82"/>
                    <measurement group_id="O4" value="1.3" spread="1.60"/>
                    <measurement group_id="O5" value="1.9" spread="1.84"/>
                    <measurement group_id="O6" value="-6.4" spread="1.83"/>
                    <measurement group_id="O7" value="1.0" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.74"/>
                    <measurement group_id="O2" value="3.4" spread="2.49"/>
                    <measurement group_id="O3" value="1.0" spread="2.46"/>
                    <measurement group_id="O4" value="0.9" spread="2.15"/>
                    <measurement group_id="O5" value="2.2" spread="2.47"/>
                    <measurement group_id="O6" value="0.8" spread="2.47"/>
                    <measurement group_id="O7" value="0.9" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.44"/>
                    <measurement group_id="O2" value="2.8" spread="2.07"/>
                    <measurement group_id="O3" value="3.4" spread="2.03"/>
                    <measurement group_id="O4" value="-2.3" spread="1.78"/>
                    <measurement group_id="O5" value="-1.4" spread="2.05"/>
                    <measurement group_id="O6" value="-2.1" spread="2.04"/>
                    <measurement group_id="O7" value="0.2" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.60"/>
                    <measurement group_id="O2" value="1.1" spread="2.29"/>
                    <measurement group_id="O3" value="4.5" spread="2.26"/>
                    <measurement group_id="O4" value="-0.1" spread="1.97"/>
                    <measurement group_id="O5" value="0.5" spread="2.27"/>
                    <measurement group_id="O6" value="-5.2" spread="2.26"/>
                    <measurement group_id="O7" value="-0.9" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.86"/>
                    <measurement group_id="O2" value="3.6" spread="2.67"/>
                    <measurement group_id="O3" value="3.7" spread="2.64"/>
                    <measurement group_id="O4" value="1.7" spread="2.30"/>
                    <measurement group_id="O5" value="-1.5" spread="2.65"/>
                    <measurement group_id="O6" value="-5.3" spread="2.64"/>
                    <measurement group_id="O7" value="-0.7" spread="2.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.67"/>
                    <measurement group_id="O2" value="3.0" spread="2.39"/>
                    <measurement group_id="O3" value="3.1" spread="2.36"/>
                    <measurement group_id="O4" value="-1.0" spread="2.06"/>
                    <measurement group_id="O5" value="-0.1" spread="2.37"/>
                    <measurement group_id="O6" value="-6.9" spread="2.36"/>
                    <measurement group_id="O7" value="-1.7" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.56"/>
                    <measurement group_id="O2" value="-1.6" spread="2.24"/>
                    <measurement group_id="O3" value="0.7" spread="2.21"/>
                    <measurement group_id="O4" value="-2.3" spread="1.93"/>
                    <measurement group_id="O5" value="-0.9" spread="2.22"/>
                    <measurement group_id="O6" value="-7.0" spread="2.21"/>
                    <measurement group_id="O7" value="-3.0" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="1.90"/>
                    <measurement group_id="O2" value="-1.8" spread="2.71"/>
                    <measurement group_id="O3" value="3.6" spread="2.68"/>
                    <measurement group_id="O4" value="-4.5" spread="2.34"/>
                    <measurement group_id="O5" value="-5.8" spread="2.69"/>
                    <measurement group_id="O6" value="-5.8" spread="2.69"/>
                    <measurement group_id="O7" value="-1.8" spread="2.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.12"/>
                    <measurement group_id="O2" value="0.4" spread="3.03"/>
                    <measurement group_id="O3" value="3.5" spread="3.00"/>
                    <measurement group_id="O4" value="-1.3" spread="2.61"/>
                    <measurement group_id="O5" value="-1.0" spread="3.01"/>
                    <measurement group_id="O6" value="-7.8" spread="3.01"/>
                    <measurement group_id="O7" value="-0.5" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.61"/>
                    <measurement group_id="O2" value="0.1" spread="2.32"/>
                    <measurement group_id="O3" value="0.8" spread="2.28"/>
                    <measurement group_id="O4" value="0.5" spread="1.99"/>
                    <measurement group_id="O5" value="-4.2" spread="2.29"/>
                    <measurement group_id="O6" value="-2.2" spread="2.29"/>
                    <measurement group_id="O7" value="-3.1" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Change From Baseline in QRS Interval</title>
        <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. The QRS complex is a combination of the Q wave, R wave and S wave on an ECG tracing, and represents ventricular depolarization. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QRS in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in QRS interval (ΔQRS) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QRS as covariate.</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The QT/QTc population with available data at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participants received a single oral dose of matching placebo in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Change From Baseline in QRS Interval</title>
          <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. The QRS complex is a combination of the Q wave, R wave and S wave on an ECG tracing, and represents ventricular depolarization. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QRS in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in QRS interval (ΔQRS) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QRS as covariate.</description>
          <population>The QT/QTc population with available data at each time point</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.21"/>
                    <measurement group_id="O2" value="0.0" spread="0.31"/>
                    <measurement group_id="O3" value="-0.4" spread="0.30"/>
                    <measurement group_id="O4" value="0.2" spread="0.26"/>
                    <measurement group_id="O5" value="-0.1" spread="0.31"/>
                    <measurement group_id="O6" value="0.1" spread="0.30"/>
                    <measurement group_id="O7" value="-.1" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.22"/>
                    <measurement group_id="O2" value="-0.1" spread="0.32"/>
                    <measurement group_id="O3" value="0.1" spread="0.32"/>
                    <measurement group_id="O4" value="0.2" spread="0.27"/>
                    <measurement group_id="O5" value="0.3" spread="0.32"/>
                    <measurement group_id="O6" value="0.2" spread="0.32"/>
                    <measurement group_id="O7" value="0.4" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.45"/>
                    <measurement group_id="O2" value="-0.2" spread="0.63"/>
                    <measurement group_id="O3" value="0.0" spread="0.63"/>
                    <measurement group_id="O4" value="0.4" spread="0.55"/>
                    <measurement group_id="O5" value="0.5" spread="0.63"/>
                    <measurement group_id="O6" value="0.3" spread="0.63"/>
                    <measurement group_id="O7" value="0.6" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.24"/>
                    <measurement group_id="O2" value="0.2" spread="0.34"/>
                    <measurement group_id="O3" value="0.1" spread="0.34"/>
                    <measurement group_id="O4" value="0.7" spread="0.29"/>
                    <measurement group_id="O5" value="0.1" spread="0.34"/>
                    <measurement group_id="O6" value="0.4" spread="0.34"/>
                    <measurement group_id="O7" value="0.8" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.24"/>
                    <measurement group_id="O2" value="0.0" spread="0.34"/>
                    <measurement group_id="O3" value="0.2" spread="0.34"/>
                    <measurement group_id="O4" value="-0.2" spread="0.30"/>
                    <measurement group_id="O5" value="0.2" spread="0.34"/>
                    <measurement group_id="O6" value="0.0" spread="0.34"/>
                    <measurement group_id="O7" value="0.3" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.22"/>
                    <measurement group_id="O2" value="0.0" spread="0.31"/>
                    <measurement group_id="O3" value="0.2" spread="0.31"/>
                    <measurement group_id="O4" value="0.1" spread="0.27"/>
                    <measurement group_id="O5" value="0.4" spread="0.31"/>
                    <measurement group_id="O6" value="0.4" spread="0.31"/>
                    <measurement group_id="O7" value="0.2" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.29"/>
                    <measurement group_id="O2" value="-0.1" spread="0.41"/>
                    <measurement group_id="O3" value="0.2" spread="0.41"/>
                    <measurement group_id="O4" value="0.5" spread="0.35"/>
                    <measurement group_id="O5" value="0.3" spread="0.41"/>
                    <measurement group_id="O6" value="0.9" spread="0.41"/>
                    <measurement group_id="O7" value="1.0" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.55"/>
                    <measurement group_id="O2" value="-0.8" spread="0.78"/>
                    <measurement group_id="O3" value="-0.5" spread="0.77"/>
                    <measurement group_id="O4" value="-0.7" spread="0.67"/>
                    <measurement group_id="O5" value="-1.3" spread="0.78"/>
                    <measurement group_id="O6" value="0.6" spread="0.77"/>
                    <measurement group_id="O7" value="0.8" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.33"/>
                    <measurement group_id="O2" value="-0.6" spread="0.47"/>
                    <measurement group_id="O3" value="-0.2" spread="0.47"/>
                    <measurement group_id="O4" value="-0.3" spread="0.41"/>
                    <measurement group_id="O5" value="-0.3" spread="0.47"/>
                    <measurement group_id="O6" value="0.2" spread="0.47"/>
                    <measurement group_id="O7" value="-0.5" spread="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="0.38"/>
                    <measurement group_id="O2" value="0.0" spread="0.54"/>
                    <measurement group_id="O3" value="0.0" spread="0.54"/>
                    <measurement group_id="O4" value="-0.3" spread="0.47"/>
                    <measurement group_id="O5" value="-0.3" spread="0.54"/>
                    <measurement group_id="O6" value="0.5" spread="0.54"/>
                    <measurement group_id="O7" value="0.5" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                    <count group_id="O7" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.39"/>
                    <measurement group_id="O2" value="0.1" spread="0.55"/>
                    <measurement group_id="O3" value="0.1" spread="0.55"/>
                    <measurement group_id="O4" value="0.4" spread="0.48"/>
                    <measurement group_id="O5" value="-0.1" spread="0.55"/>
                    <measurement group_id="O6" value="0.0" spread="0.55"/>
                    <measurement group_id="O7" value="-0.7" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval</title>
        <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
QT interval was corrected for heart rate using Fridericia's correction (QTcF). Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔQTcF) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QTcF as covariate.&#xD;
Placebo-corrected ΔQTcF (ΔΔQTcF) was calculated as the adjusted mean ΔQTcF in the S-648414 group minus adjusted mean ΔQTcF in the placebo group at each time point.</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The QT/QTc population with available data at each time point. The number of participants analyzed includes participants in each S-648414 group with available data; reported values are corrected for placebo data collected for the 12 participants in the Part 1 Placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Placebo-corrected Change From Baseline in Fridericia's Corrected QT Interval</title>
          <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QT in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
QT interval was corrected for heart rate using Fridericia's correction (QTcF). Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔQTcF) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QTcF as covariate.&#xD;
Placebo-corrected ΔQTcF (ΔΔQTcF) was calculated as the adjusted mean ΔQTcF in the S-648414 group minus adjusted mean ΔQTcF in the placebo group at each time point.</description>
          <population>The QT/QTc population with available data at each time point. The number of participants analyzed includes participants in each S-648414 group with available data; reported values are corrected for placebo data collected for the 12 participants in the Part 1 Placebo group.</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.98"/>
                    <measurement group_id="O2" value="-2.4" spread="1.99"/>
                    <measurement group_id="O3" value="-1.6" spread="1.81"/>
                    <measurement group_id="O4" value="-0.9" spread="1.98"/>
                    <measurement group_id="O5" value="-2.4" spread="2.10"/>
                    <measurement group_id="O6" value="5.2" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="2.04"/>
                    <measurement group_id="O2" value="-0.2" spread="2.06"/>
                    <measurement group_id="O3" value="-1.0" spread="1.87"/>
                    <measurement group_id="O4" value="1.2" spread="2.04"/>
                    <measurement group_id="O5" value="1.1" spread="2.16"/>
                    <measurement group_id="O6" value="7.0" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.40"/>
                    <measurement group_id="O2" value="-1.5" spread="2.41"/>
                    <measurement group_id="O3" value="0.0" spread="2.20"/>
                    <measurement group_id="O4" value="3.0" spread="2.40"/>
                    <measurement group_id="O5" value="4.2" spread="2.50"/>
                    <measurement group_id="O6" value="6.0" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.37"/>
                    <measurement group_id="O2" value="-0.9" spread="2.38"/>
                    <measurement group_id="O3" value="-1.8" spread="2.16"/>
                    <measurement group_id="O4" value="-1.1" spread="2.36"/>
                    <measurement group_id="O5" value="2.5" spread="2.46"/>
                    <measurement group_id="O6" value="6.4" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.38"/>
                    <measurement group_id="O2" value="1.0" spread="2.39"/>
                    <measurement group_id="O3" value="1.4" spread="2.18"/>
                    <measurement group_id="O4" value="2.8" spread="2.38"/>
                    <measurement group_id="O5" value="5.0" spread="2.48"/>
                    <measurement group_id="O6" value="10.4" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="2.13"/>
                    <measurement group_id="O2" value="0.5" spread="2.14"/>
                    <measurement group_id="O3" value="1.2" spread="1.94"/>
                    <measurement group_id="O4" value="4.5" spread="2.12"/>
                    <measurement group_id="O5" value="1.4" spread="2.24"/>
                    <measurement group_id="O6" value="12.0" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="2.65"/>
                    <measurement group_id="O2" value="1.7" spread="2.66"/>
                    <measurement group_id="O3" value="2.4" spread="2.42"/>
                    <measurement group_id="O4" value="2.5" spread="2.65"/>
                    <measurement group_id="O5" value="5.9" spread="2.74"/>
                    <measurement group_id="O6" value="14.3" spread="2.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="4.36"/>
                    <measurement group_id="O2" value="3.0" spread="4.36"/>
                    <measurement group_id="O3" value="4.0" spread="3.98"/>
                    <measurement group_id="O4" value="0.7" spread="4.36"/>
                    <measurement group_id="O5" value="0.6" spread="4.41"/>
                    <measurement group_id="O6" value="8.1" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="2.95"/>
                    <measurement group_id="O2" value="3.7" spread="2.96"/>
                    <measurement group_id="O3" value="0.9" spread="2.70"/>
                    <measurement group_id="O4" value="-1.8" spread="2.95"/>
                    <measurement group_id="O5" value="0.7" spread="3.03"/>
                    <measurement group_id="O6" value="9.1" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.21"/>
                    <measurement group_id="O2" value="1.8" spread="4.22"/>
                    <measurement group_id="O3" value="1.8" spread="3.85"/>
                    <measurement group_id="O4" value="-0.5" spread="4.21"/>
                    <measurement group_id="O5" value="-2.1" spread="4.27"/>
                    <measurement group_id="O6" value="9.6" spread="4.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="2.04"/>
                    <measurement group_id="O2" value="0.2" spread="2.05"/>
                    <measurement group_id="O3" value="-0.7" spread="1.86"/>
                    <measurement group_id="O4" value="0.5" spread="2.03"/>
                    <measurement group_id="O5" value="-0.4" spread="2.15"/>
                    <measurement group_id="O6" value="8.8" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Placebo-corrected Change From Baseline in Heart Rate</title>
        <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median HR in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured values from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔHR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline HR as covariate.&#xD;
Placebo-corrected ΔHR (ΔΔHR) was calculated as the adjusted mean ΔHR in the S-648414 group minus adjusted mean ΔHR in the placebo group at each time point.</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The QT/QTc population with available data at each time point. The number of participants analyzed includes participants in each S-648414 group with available data; reported values are corrected for placebo data collected for the 12 participants in the Part 1 Placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Placebo-corrected Change From Baseline in Heart Rate</title>
          <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median HR in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured values from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔHR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline HR as covariate.&#xD;
Placebo-corrected ΔHR (ΔΔHR) was calculated as the adjusted mean ΔHR in the S-648414 group minus adjusted mean ΔHR in the placebo group at each time point.</description>
          <population>The QT/QTc population with available data at each time point. The number of participants analyzed includes participants in each S-648414 group with available data; reported values are corrected for placebo data collected for the 12 participants in the Part 1 Placebo group.</population>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="1.93"/>
                    <measurement group_id="O2" value="-2.3" spread="1.95"/>
                    <measurement group_id="O3" value="-2.0" spread="1.76"/>
                    <measurement group_id="O4" value="-1.0" spread="1.92"/>
                    <measurement group_id="O5" value="-1.6" spread="1.93"/>
                    <measurement group_id="O6" value="-2.5" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="2.00"/>
                    <measurement group_id="O2" value="-3.4" spread="2.03"/>
                    <measurement group_id="O3" value="-3.5" spread="1.83"/>
                    <measurement group_id="O4" value="-1.1" spread="2.00"/>
                    <measurement group_id="O5" value="-2.5" spread="2.00"/>
                    <measurement group_id="O6" value="-2.2" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="2.04"/>
                    <measurement group_id="O2" value="0.1" spread="2.07"/>
                    <measurement group_id="O3" value="-2.6" spread="1.86"/>
                    <measurement group_id="O4" value="0.0" spread="2.04"/>
                    <measurement group_id="O5" value="0.6" spread="2.04"/>
                    <measurement group_id="O6" value="0.0" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="2.26"/>
                    <measurement group_id="O2" value="-2.0" spread="2.28"/>
                    <measurement group_id="O3" value="-2.1" spread="2.06"/>
                    <measurement group_id="O4" value="-1.3" spread="2.26"/>
                    <measurement group_id="O5" value="0.9" spread="2.26"/>
                    <measurement group_id="O6" value="0.1" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.22"/>
                    <measurement group_id="O2" value="-3.8" spread="2.25"/>
                    <measurement group_id="O3" value="-3.0" spread="2.03"/>
                    <measurement group_id="O4" value="-1.5" spread="2.22"/>
                    <measurement group_id="O5" value="2.0" spread="2.22"/>
                    <measurement group_id="O6" value="-1.5" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="2.39"/>
                    <measurement group_id="O2" value="-0.7" spread="2.41"/>
                    <measurement group_id="O3" value="-1.2" spread="2.18"/>
                    <measurement group_id="O4" value="-0.8" spread="2.39"/>
                    <measurement group_id="O5" value="2.9" spread="2.39"/>
                    <measurement group_id="O6" value="0.4" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.45"/>
                    <measurement group_id="O2" value="0.4" spread="2.47"/>
                    <measurement group_id="O3" value="-3.1" spread="2.23"/>
                    <measurement group_id="O4" value="0.6" spread="2.45"/>
                    <measurement group_id="O5" value="1.9" spread="2.45"/>
                    <measurement group_id="O6" value="3.1" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.05"/>
                    <measurement group_id="O2" value="-2.8" spread="2.07"/>
                    <measurement group_id="O3" value="-1.0" spread="1.87"/>
                    <measurement group_id="O4" value="-1.5" spread="2.05"/>
                    <measurement group_id="O5" value="2.0" spread="2.05"/>
                    <measurement group_id="O6" value="2.3" spread="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.70"/>
                    <measurement group_id="O2" value="-0.9" spread="2.72"/>
                    <measurement group_id="O3" value="-1.7" spread="2.46"/>
                    <measurement group_id="O4" value="0.3" spread="2.70"/>
                    <measurement group_id="O5" value="3.1" spread="2.70"/>
                    <measurement group_id="O6" value="2.0" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="3.12"/>
                    <measurement group_id="O2" value="-0.7" spread="3.14"/>
                    <measurement group_id="O3" value="-1.5" spread="2.85"/>
                    <measurement group_id="O4" value="-0.3" spread="3.12"/>
                    <measurement group_id="O5" value="6.4" spread="3.12"/>
                    <measurement group_id="O6" value="0.7" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="2.85"/>
                    <measurement group_id="O2" value="-0.9" spread="2.87"/>
                    <measurement group_id="O3" value="-1.9" spread="2.60"/>
                    <measurement group_id="O4" value="0.4" spread="2.85"/>
                    <measurement group_id="O5" value="-0.1" spread="2.85"/>
                    <measurement group_id="O6" value="2.9" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Placebo-corrected Change From Baseline in PR Interval</title>
        <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median PR interval in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔPR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline PR as covariate.&#xD;
Placebo-corrected ΔPR (ΔΔPR) was calculated as the adjusted mean ΔPR in the S-648414 group minus adjusted mean ΔPR in the placebo group at each time point.</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The QT/QTc population with available data at each time point. The number of participants analyzed includes participants in each S-648414 group with available data; reported values are corrected for placebo data collected for the 12 participants in the Part 1 Placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Placebo-corrected Change From Baseline in PR Interval</title>
          <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median PR interval in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline (ΔPR) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline PR as covariate.&#xD;
Placebo-corrected ΔPR (ΔΔPR) was calculated as the adjusted mean ΔPR in the S-648414 group minus adjusted mean ΔPR in the placebo group at each time point.</description>
          <population>The QT/QTc population with available data at each time point. The number of participants analyzed includes participants in each S-648414 group with available data; reported values are corrected for placebo data collected for the 12 participants in the Part 1 Placebo group.</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.28"/>
                    <measurement group_id="O2" value="1.8" spread="2.24"/>
                    <measurement group_id="O3" value="-0.5" spread="2.06"/>
                    <measurement group_id="O4" value="0.9" spread="2.25"/>
                    <measurement group_id="O5" value="-4.3" spread="2.25"/>
                    <measurement group_id="O6" value="-0.4" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.27"/>
                    <measurement group_id="O2" value="3.2" spread="2.23"/>
                    <measurement group_id="O3" value="0.5" spread="2.05"/>
                    <measurement group_id="O4" value="1.0" spread="2.24"/>
                    <measurement group_id="O5" value="-7.2" spread="2.23"/>
                    <measurement group_id="O6" value="0.2" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="3.04"/>
                    <measurement group_id="O2" value="0.6" spread="3.02"/>
                    <measurement group_id="O3" value="0.5" spread="2.76"/>
                    <measurement group_id="O4" value="1.8" spread="3.02"/>
                    <measurement group_id="O5" value="0.4" spread="3.02"/>
                    <measurement group_id="O6" value="0.5" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.52"/>
                    <measurement group_id="O2" value="2.6" spread="2.49"/>
                    <measurement group_id="O3" value="-3.1" spread="2.29"/>
                    <measurement group_id="O4" value="-2.2" spread="2.50"/>
                    <measurement group_id="O5" value="-2.9" spread="2.49"/>
                    <measurement group_id="O6" value="-0.6" spread="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.79"/>
                    <measurement group_id="O2" value="3.8" spread="2.77"/>
                    <measurement group_id="O3" value="-0.8" spread="2.54"/>
                    <measurement group_id="O4" value="-0.2" spread="2.78"/>
                    <measurement group_id="O5" value="-5.9" spread="2.77"/>
                    <measurement group_id="O6" value="-1.6" spread="2.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="3.25"/>
                    <measurement group_id="O2" value="3.8" spread="3.23"/>
                    <measurement group_id="O3" value="1.8" spread="2.96"/>
                    <measurement group_id="O4" value="-1.4" spread="3.24"/>
                    <measurement group_id="O5" value="-5.2" spread="3.23"/>
                    <measurement group_id="O6" value="-0.5" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.91"/>
                    <measurement group_id="O2" value="2.7" spread="2.89"/>
                    <measurement group_id="O3" value="-1.5" spread="2.65"/>
                    <measurement group_id="O4" value="-0.5" spread="2.90"/>
                    <measurement group_id="O5" value="-7.4" spread="2.89"/>
                    <measurement group_id="O6" value="-2.2" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.74"/>
                    <measurement group_id="O2" value="3.5" spread="2.71"/>
                    <measurement group_id="O3" value="0.5" spread="2.48"/>
                    <measurement group_id="O4" value="1.9" spread="2.72"/>
                    <measurement group_id="O5" value="-4.1" spread="2.71"/>
                    <measurement group_id="O6" value="-0.1" spread="2.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="3.31"/>
                    <measurement group_id="O2" value="6.8" spread="3.28"/>
                    <measurement group_id="O3" value="-1.3" spread="3.01"/>
                    <measurement group_id="O4" value="-2.6" spread="3.29"/>
                    <measurement group_id="O5" value="-2.6" spread="3.29"/>
                    <measurement group_id="O6" value="1.4" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="3.70"/>
                    <measurement group_id="O2" value="4.5" spread="3.68"/>
                    <measurement group_id="O3" value="-0.4" spread="3.37"/>
                    <measurement group_id="O4" value="-0.1" spread="3.69"/>
                    <measurement group_id="O5" value="-6.9" spread="3.68"/>
                    <measurement group_id="O6" value="0.4" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.82"/>
                    <measurement group_id="O2" value="2.2" spread="2.79"/>
                    <measurement group_id="O3" value="2.0" spread="2.56"/>
                    <measurement group_id="O4" value="-2.7" spread="2.80"/>
                    <measurement group_id="O5" value="-0.7" spread="2.80"/>
                    <measurement group_id="O6" value="-1.6" spread="2.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Placebo-corrected Change From Baseline in QRS Duration</title>
        <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QRS duration in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in QRS duration (ΔQRS) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QRS as covariate.&#xD;
Placebo-corrected ΔQRS (ΔΔQRS) was calculated as the adjusted mean ΔQRS in the S-648414 group minus adjusted mean ΔQRS in the placebo group at each time point.</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>The QT/QTc population with available data at each time point. The number of participants analyzed includes participants in each S-648414 group with available data; reported values are corrected for placebo data collected for the 12 participants in the Part 1 Placebo group.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Placebo-corrected Change From Baseline in QRS Duration</title>
          <description>Continuous 12-lead digital electrocardiogram (ECG) recording was performed on Day 1. ECGs were analyzed at a blinded, central ECG laboratory. At each specified time point, ten 14-second 12-lead ECG tracings were extracted from the continuous recordings. The median QRS duration in each replicate was calculated; the mean of available medians was used as the participant's reportable value at that time point.&#xD;
Baseline was defined as the average of the measured ECG intervals from the 3 pre-dose time points (45, 30, and 15 minutes before dosing) on Day 1.&#xD;
Change from Baseline in QRS duration (ΔQRS) was calculated based on a linear mixed-effects model with time (categorical), treatment, and time-by-treatment interaction as fixed effects and Baseline QRS as covariate.&#xD;
Placebo-corrected ΔQRS (ΔΔQRS) was calculated as the adjusted mean ΔQRS in the S-648414 group minus adjusted mean ΔQRS in the placebo group at each time point.</description>
          <population>The QT/QTc population with available data at each time point. The number of participants analyzed includes participants in each S-648414 group with available data; reported values are corrected for placebo data collected for the 12 participants in the Part 1 Placebo group.</population>
          <units>ms</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.37"/>
                    <measurement group_id="O2" value="-0.1" spread="0.37"/>
                    <measurement group_id="O3" value="0.5" spread="0.34"/>
                    <measurement group_id="O4" value="0.2" spread="0.37"/>
                    <measurement group_id="O5" value="0.4" spread="0.37"/>
                    <measurement group_id="O6" value="0.2" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.39"/>
                    <measurement group_id="O2" value="0.5" spread="0.39"/>
                    <measurement group_id="O3" value="0.6" spread="0.35"/>
                    <measurement group_id="O4" value="0.7" spread="0.39"/>
                    <measurement group_id="O5" value="0.6" spread="0.39"/>
                    <measurement group_id="O6" value="0.8" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="0.77"/>
                    <measurement group_id="O2" value="-0.6" spread="0.77"/>
                    <measurement group_id="O3" value="-0.1" spread="0.71"/>
                    <measurement group_id="O4" value="-0.1" spread="0.77"/>
                    <measurement group_id="O5" value="-0.3" spread="0.77"/>
                    <measurement group_id="O6" value="0.0" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.42"/>
                    <measurement group_id="O2" value="0.4" spread="0.42"/>
                    <measurement group_id="O3" value="1.1" spread="0.38"/>
                    <measurement group_id="O4" value="0.5" spread="0.42"/>
                    <measurement group_id="O5" value="0.7" spread="0.42"/>
                    <measurement group_id="O6" value="1.1" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.42"/>
                    <measurement group_id="O2" value="0.3" spread="0.42"/>
                    <measurement group_id="O3" value="-0.1" spread="0.38"/>
                    <measurement group_id="O4" value="0.3" spread="0.42"/>
                    <measurement group_id="O5" value="0.1" spread="0.42"/>
                    <measurement group_id="O6" value="0.4" spread="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.38"/>
                    <measurement group_id="O2" value="0.4" spread="0.38"/>
                    <measurement group_id="O3" value="0.3" spread="0.35"/>
                    <measurement group_id="O4" value="0.5" spread="0.38"/>
                    <measurement group_id="O5" value="0.5" spread="0.38"/>
                    <measurement group_id="O6" value="0.3" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.50"/>
                    <measurement group_id="O2" value="0.0" spread="0.50"/>
                    <measurement group_id="O3" value="0.3" spread="0.46"/>
                    <measurement group_id="O4" value="0.1" spread="0.50"/>
                    <measurement group_id="O5" value="0.8" spread="0.50"/>
                    <measurement group_id="O6" value="0.8" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.95"/>
                    <measurement group_id="O2" value="0.0" spread="0.95"/>
                    <measurement group_id="O3" value="-0.2" spread="0.87"/>
                    <measurement group_id="O4" value="-0.8" spread="0.95"/>
                    <measurement group_id="O5" value="1.1" spread="0.95"/>
                    <measurement group_id="O6" value="1.3" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.58"/>
                    <measurement group_id="O2" value="0.7" spread="0.58"/>
                    <measurement group_id="O3" value="0.5" spread="0.53"/>
                    <measurement group_id="O4" value="0.5" spread="0.58"/>
                    <measurement group_id="O5" value="1.1" spread="0.58"/>
                    <measurement group_id="O6" value="0.3" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="0.66"/>
                    <measurement group_id="O2" value="1.4" spread="0.66"/>
                    <measurement group_id="O3" value="1.1" spread="0.60"/>
                    <measurement group_id="O4" value="1.1" spread="0.66"/>
                    <measurement group_id="O5" value="1.9" spread="0.66"/>
                    <measurement group_id="O6" value="1.9" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours postdose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                    <count group_id="O6" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.68"/>
                    <measurement group_id="O2" value="0.8" spread="0.67"/>
                    <measurement group_id="O3" value="1.1" spread="0.62"/>
                    <measurement group_id="O4" value="0.6" spread="0.68"/>
                    <measurement group_id="O5" value="0.7" spread="0.67"/>
                    <measurement group_id="O6" value="0.0" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Recorded Outlier Values for QTcF, HR, PR, and QRS</title>
        <description>A participant was determined as an outlier if the following criteria (assessed separately) were met for the ECG intervals at any time point:&#xD;
QTcF:&#xD;
Treatment-emergent value of &gt; 450 and ≤ 480 ms when not present at Baseline (new onset)&#xD;
Treatment-emergent value of &gt; 480 and ≤ 500 ms when not present at Baseline (new onset)&#xD;
Treatment-emergent value of &gt; 500 ms when not present at Baseline (new onset)&#xD;
Increase of QTcF (ΔQTcF) from Baseline of &gt; 30 and ≤ 60 ms&#xD;
Increase of QTcF from Baseline &gt; 60 ms&#xD;
HR:&#xD;
Decrease of HR from Baseline &gt; 25% resulting in HR &lt; 50 bpm&#xD;
Increase of HR from Baseline &gt; 25% resulting in HR &gt; 100 bpm&#xD;
PR:&#xD;
Increase of PR from Baseline &gt; 25% resulting in PR &gt; 200 ms&#xD;
QRS:&#xD;
Increase of QRS from Baseline &gt; 25% resulting in QRS &gt; 120 ms</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>QT/QTc population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participants received a single oral dose of matching placebo in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Recorded Outlier Values for QTcF, HR, PR, and QRS</title>
          <description>A participant was determined as an outlier if the following criteria (assessed separately) were met for the ECG intervals at any time point:&#xD;
QTcF:&#xD;
Treatment-emergent value of &gt; 450 and ≤ 480 ms when not present at Baseline (new onset)&#xD;
Treatment-emergent value of &gt; 480 and ≤ 500 ms when not present at Baseline (new onset)&#xD;
Treatment-emergent value of &gt; 500 ms when not present at Baseline (new onset)&#xD;
Increase of QTcF (ΔQTcF) from Baseline of &gt; 30 and ≤ 60 ms&#xD;
Increase of QTcF from Baseline &gt; 60 ms&#xD;
HR:&#xD;
Decrease of HR from Baseline &gt; 25% resulting in HR &lt; 50 bpm&#xD;
Increase of HR from Baseline &gt; 25% resulting in HR &gt; 100 bpm&#xD;
PR:&#xD;
Increase of PR from Baseline &gt; 25% resulting in PR &gt; 200 ms&#xD;
QRS:&#xD;
Increase of QRS from Baseline &gt; 25% resulting in QRS &gt; 120 ms</description>
          <population>QT/QTc population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>QTcF &gt; 450 and ≤ 480 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF &gt; 480 and ≤ 500 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTcF &gt; 500 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ΔQTcF &gt; 30 and ≤ 60 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ΔQTcF &gt; 60 ms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR &lt; 50 (bpm) with a decrease in ΔHR &gt; 25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR &gt; 100 (bpm) with an increase in ΔHR &gt; 25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR &gt; 200 (ms) with an increase in ΔPR &gt; 25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS &gt; 120 (ms) with an increase in ΔQRS &gt; 25%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1: Number of Participants With Treatment-emergent Changes for T-wave Morphology and U-wave Presence</title>
        <description>T-wave abnormalities were categorized as follows:&#xD;
Normal T wave: Any positive T wave not meeting any criterion below&#xD;
Flat T wave: T amplitude &lt; 1 mm (either positive or negative) including flat isoelectric line&#xD;
Notched T wave (+): Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of the positive T wave&#xD;
Biphasic: T wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T waves included)&#xD;
Normal T wave (-): T amplitude that is negative, without biphasic T wave or notches&#xD;
Notched T wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T wave&#xD;
U waves: Presence of abnormal U waves</description>
        <time_frame>Day 1: Predose at 3 time points (-45, -30 and -15 minutes), and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>QT/QTc population)</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo</title>
            <description>Participants received a single oral dose of matching placebo in a fasted state on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: 10 mg S-648414</title>
            <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: 30 mg S-648414</title>
            <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: 100 mg S-648414</title>
            <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: 250 mg S-648414</title>
            <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: 500 mg S-648414</title>
            <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: 1000 mg S-648414</title>
            <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1: Number of Participants With Treatment-emergent Changes for T-wave Morphology and U-wave Presence</title>
          <description>T-wave abnormalities were categorized as follows:&#xD;
Normal T wave: Any positive T wave not meeting any criterion below&#xD;
Flat T wave: T amplitude &lt; 1 mm (either positive or negative) including flat isoelectric line&#xD;
Notched T wave (+): Presence of notch(es) of at least 0.05 mV amplitude on ascending or descending arm of the positive T wave&#xD;
Biphasic: T wave that contains a second component with an opposite phase that is at least 0.1 mV deep (both positive/negative and negative/positive and polyphasic T waves included)&#xD;
Normal T wave (-): T amplitude that is negative, without biphasic T wave or notches&#xD;
Notched T wave (-): Presence of notch(es) of at least 0.05 mV amplitude on descending or ascending arm of the negative T wave&#xD;
U waves: Presence of abnormal U waves</description>
          <population>QT/QTc population)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Flat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notched (+)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biphasic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal (-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Notched (-)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>U-Wave presence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Part 1: From dosing on Day 1 or Day 14 up to 10 days post dose; Part 2: From the first dose up to 10 days after end of dosing (25 days); Part 3: From the first dose up to Day 36. A TEAE was summarized to a given treatment if the event onset/worsening occurred any time after the dose of that treatment and before the dose of the next treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Placebo - Fasted</title>
          <description>Participants received a single oral dose of matching placebo in a fasted state on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: Placebo - Fed</title>
          <description>Participants received a single dose of matching placebo in a fed state (after a high-fat meal) on Day 14.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: 10 mg S-648414</title>
          <description>Participants received a single oral dose of 10 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: 30 mg S-648414</title>
          <description>Participants received a single oral dose of 30 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 1: 100 mg S-648414 Fasted</title>
          <description>Participants received a single oral dose of 100 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Part 1: 100 mg S-648414 Fed</title>
          <description>Participants received a single oral dose of 100 mg S-648414 in a fed state (after a high-fat meal) on Day 14.</description>
        </group>
        <group group_id="E7">
          <title>Part 1: 250 mg S-648414</title>
          <description>Participants received a single oral dose of 250 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>Part 1: 500 mg S-648414</title>
          <description>Participants received a single oral dose of 500 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="E9">
          <title>Part 1: 1000 mg S-648414</title>
          <description>Participants received a single oral dose of 1000 mg S-648414 in a fasted state on Day 1.</description>
        </group>
        <group group_id="E10">
          <title>Part 2: Midazolam (Day -2)</title>
          <description>Participants received a single oral dose of 5 mg midazolam on Day -2</description>
        </group>
        <group group_id="E11">
          <title>Part 2: Placebo (Days 1-13)</title>
          <description>Participants received matching placebo to S-648414 once a day on Days 1 to 13.</description>
        </group>
        <group group_id="E12">
          <title>Part 2: 50 mg S-648414 (Days 1-13)</title>
          <description>Participants received 50 mg S-648414 once a day on Days 1 to 13.</description>
        </group>
        <group group_id="E13">
          <title>Part 2: 30 mg S-648414 (Days 1-13)</title>
          <description>Participants received 30 mg S-648414 once a day on Days 1 to 13.</description>
        </group>
        <group group_id="E14">
          <title>Part 2: Placebo + Midazolam (Day 14)</title>
          <description>Participants received matching placebo to S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
        </group>
        <group group_id="E15">
          <title>Part 2: 50 mg S-648414 + Midazolam (Day 14)</title>
          <description>Participants received 50 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
        </group>
        <group group_id="E16">
          <title>Part 2: 30 mg S-648414 + Midazolam (Day 14)</title>
          <description>Participants received 30 mg S-648414 and a single oral dose of 5 mg midazolam on Day 14.</description>
        </group>
        <group group_id="E17">
          <title>Part 3: Group I Dolutegravir</title>
          <description>Participants received 50 mg dolutegravir orally once a day on Days 1 to 7.</description>
        </group>
        <group group_id="E18">
          <title>Part 3: 100 mg S-648414</title>
          <description>Participants received 100 mg S-648414 orally once a day on Days 15 to 21.</description>
        </group>
        <group group_id="E19">
          <title>Part 3: 100 mg S-648414 + Dolutegravir</title>
          <description>Participants received 50 mg dolutegravir co-administered with 100 mg S-648414 orally once a day on Days 22 to 28.</description>
        </group>
        <group group_id="E20">
          <title>Part 3: Dolutegravir</title>
          <description>Participants received 50 mg dolutegravir once a day on Days 1 to 7.</description>
        </group>
        <group group_id="E21">
          <title>Part 3: 200 mg S-648414</title>
          <description>Participants received 200 mg S-648414 orally once a day on Days 15 to 21.</description>
        </group>
        <group group_id="E22">
          <title>Part 3: 200 mg S-648414 + Dolutegravir</title>
          <description>Participants received 50 mg dolutegravir once a day co-administered with 200 mg S-648414 orally once a day on Days 22 to 28.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (23.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E18" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E19" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E20" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E21" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E22" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can embargo results from a PI's center until the combined results from the completed study have been published in full or the sponsor confirms there will be no multicenter study publication. Results communications must be provided to the sponsor for review at least 60 days before submission for publication. By written request, the sponsor can extend the embargo up to an additional 60 days. The sponsor cannot require changes to scientific content and cannot further extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Shionogi Clinical Trials Administrator</name_or_title>
      <organization>Shionogi Inc.</organization>
      <phone>800-849-9707</phone>
      <email>shionogiclintrials-admin@shionogi.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

